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Héctor R. Morbidoni 
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CIUNR, Universidad Nacional de Rosario,  
Argentina 
And, as his strength 
Failed him at length, 
He met a pilgrim shadow -- 
"Shadow," said he, 
"Where can it be -- 
This land of El Dorado?" 
"Over the Mountains 
Of the Moon, 
Down the Valley of the Shadow, 
Ride, boldly ride," 
The shade replied -- 
"If you seek for El Dorado." 
Edgar Allan Poe, “El Dorado” 
1. Introduction 
1.1 The enemy, the battlefield and the death toll 
Mycobacterium tuberculosis, the ethiological agent of human tuberculosis, is still one of the 
most effective human pathogens, and along with the causative agent of malaria, Plasmodium 
falciparum, and the HIV virus, conform a triad of killers that merciless strike the human race. 
Current statistics show that in 2007 these three pathogens took the life of almost 5 million 
people; the majority of the cases (nearly 3 million people) affecting Africa and specially 
children (1,8 million deaths). Of these three agents, the tubercle bacilli is perhaps the one 
that spreads with more efficiency since it infects humans by aerial route, through 
aerosolized drops produced by coughing tuberculosis patients. Measures for intervention 
can be designed in the case of malaria (fighting against the transmission vector and its 
environment) and HIV (proper sex conduct, condom usage) but are much harder to 
elaborate in order to prevent people suffering of tuberculosis from coughing. Having a very 
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low infective dose (1-5 live bacilli), M. tuberculosis is able to infect a person very efficiently, 
overcoming the disadvantage of not having so far, an identified reservoir in nature. 
Once considered an eradicated disease, tuberculosis has been around for centuries; modern 
genetic techniques allowed to follow and understand the evolution of M. tuberculosis, from 
an hypothetical ancestral strain that evolved from being an environmental strain to the 
contemporary human pathogen (Brosch,R. et al., 2002; Mostowy,S., 2002, Gutierrez, M.C, et 
al., 2005; Smith, N. H., 2009). Although more detailed publications in the field of 
mechanisms of pathogenesis and immunology have been published (Kaufmann, S. H. and J. 
Hess. 2000; Collins, H. L. and S. H. Kaufmann. 2001, Ulrichs, T. and S. H. Kaufmann, 2002; 
Kaufmann, S. H. 2006) a brief description of the events taking place after the bacilli are 
inhaled as droplets from the atmosphere is described next. After travelling to the lungs, the 
microorganisms are phagocytosed by alveolar macrophages, triggering a local 
proinflammatory response that in turn causes the recruitment of mononuclear cells from 
adjacent blood vessels. These cells are the basic components of the granuloma, which 
consists of bacilli-infected macrophages surrounded by foamy (lipid loaded) macrophages 
and other mononuclear phagocytes, lymphocytes, collagen and other extracellular matrix 
components that form the periphery of the structure (Russell, D. G., 2009). This description 
corresponds to a phase of the infection in which there is no transmission of the disease 
neither clinical signs. Later on, the granuloma thickens due to a fibrous cover, becoming 
hypoxic. Several natural or disease provoked causes such as age, malnourishment, or 
conditions that impair the normal immune function, lead to major changes in the 
granuloma, that liquifies, loosing structure and releasing the caseum and large numbers of 
viable, infectious bacilli into the airways. By this process, the tubercle bacilli leaves the 
infected host and begin a new journey to the following inhalation victim. 
2. Old meets new: A powerful face-lift of anti-tubercular drugs 
The objective of this section is to describe the features of several anti-tubercular drugs that 
are still or have once been used for clinical treatment of tuberculosis as well as novel 
compounds inspired by research on those drugs. The reader is directed to several reviews in 
which those drugs are described in detail (Zhang, Y. and D. Mitchison. 2003; Vilcheze, C. 
and W. R. Jacobs, Jr. 2007). 
The advent of chemotherapy in the late 19th and early 20th centuries led to the use of 
different chemicals as options to empirically treat infectious diseases; tuberculosis was not 
the exemption and dyes such as trypan red and methylene blue were used for treatment on 
the basis that they could bind the tubercle bacilli in tissues. In the early 1930, the 
introduction of sulfonamides and their antibacterial effect led to the testing of several 
compounds against M. tuberculosis, amongst them thiosemicarbazones and sulfones such as 
Promin and Diasone. The results were discouraging so the discovery of streptomycin by 
Waksman in 1944 and its activity against the tubercle bacilli brought hope that at last an 
efficaceous drug to kill M. tuberculosis had been found. Shortly after the onset of the 
treatment, resistance to streptomycin began to develop, but a new drug, p-aminosalycilic 
acid (PAS), was generated in 1946 on the basis of the known activity of salycilic acid 
derivatives against M. tuberculosis. During those early years of tuberculosis chemotherapy, 
other drugs were added to the armamentarium, all of them found by broad screening; 
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among them we may cite Viomycin, Isoniazid, D-Cycloserine and Pyrazinamide in 1951-52, 
Ethionamide in 1956, Kanamycin in 1957, Ethambutol and Capreomycin in 1962 (Laughon, 
B. 2007). One of those drugs, the flagship of the anti-tubercular treatment, Isoniazid 
(isonicotinic acid hydrazide) displayed excellent activity and was well tolerated alone or in 
combination with Streptomycin and PAS or pyrazinamide. From that point on, only one 
drug, Rifampicin, was added to improve tuberculosis treatment. This event took place in 
1966 and was the last addition of a drug showing the desirable features of high activity, low 
toxicity and oral route of administration. Both Isoniazid and Rifampicin became the pillars 
of the anti-tubercular treatment in spite of the little knowledge on their mode and 
mechanisms of action. Thus, a first-line of defense against M. tuberculosis was built, 
consisting of the so-called first-line drugs: Isoniazid, Rifampicin, Ethambutol, Pyrazinamide 
and Streptomycin. A second group of drugs included several antibacterial drugs with 
activity against M. tuberculosis such as aminoglycosides, fluoroquinolones and D-
Cycloserine, as well as Ethionamide, an Isoniazid analogue with less potency. A third group 
of less frequently used drugs (such as Isoxyl and Thiacetazone) was later on discarded due 
to secondary effects and rapid generation of resistance. All the mentioned drugs had to wait 
over 40 years to have their mechanisms of action partially understood as will be described 
below in this section. 
During the following 30 years there was little interest from the pharmaceutical industry to 
develop novel anti-tubercular drugs, most likely because there was a general belief that 
tuberculosis cases were decreasing every year and infecting strains were in the vast 
majority, susceptible to the available first- and second- line drugs. Along with this 
perception, an important factor to decide whether or not start an anti-tubercular drug 
discovery program resided in the poor knowledge of the mycobacterial physiology and cell 
structure, necessary elements at the moment of deciphering the mechanisms of action of the 
anti-tubercular drugs and the mechanisms of resistance put forward by M. tuberculosis to 
avoid the activity of those drugs. In turn, that deficit was caused by the lack of genetic tools 
needed to manipulate mycobacteria, a situation that radically changed in the late ´90 due to 
the combined efforts of research groups in Europe and USA. The tools devised for the 
analysis of M. tuberculosis (Guilhot et al., 1994; Jackson et al., 2001; Bardarov et al., 2002) and 
the sequencing of its genome started to put the intricacies of this sophisticated pathogen 
under a spotlight (Cole et al., 1998). Part of those sophistications included a highly 
specialized genome with a large number of genes involved in synthesis, modification or 
degradation of fatty acids, underscoring the importance of those components for the 
metabolism, structure and virulence of the tubercle bacilli (Wayne and Lin, 1982, Munoz-
Elias and McKinney, 2005; Russell et al. 2009) (10-12). It was also surprising to detect the 
presence of two fatty acid synthase systems, designated FASI and FASII. FASI is an 
eukaryotic type synthase, producing as end products, fatty acids of 16-24 carbons in length, 
while FASII, is a bacterial type synthase that is in charge of the synthesis of very long chain 
fatty acids known as mycolic acids (Bloch 1975, 1977). The presence of these two systems can 
be interpreted as a sign of the specialization and co-evolution of M. tuberculosis, reflecting 
the long time interaction with humans. Thus, an increasing knowledge of the structure of 
the mycobacterial cell wall envelope accentuated the key role played by mycolic acids, 
involved in cell integrity and responsible in part for the extremely low cell wall permeability 
displayed by mycobacteria.  
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The combined effort of several labs shed light into the mechanism of action of the most 
prominent anti-tubercular drugs in use, namely, Isoniazid (INH), Ethionamide (ETH), 
Ethambutol (EMB) and Pyrazinamide (PZA). In brief, INH and ETH have a common target, 
an Enoyl Acyl Carrier Protein (ACP) Reductase dubbed InhA, part of the FASII cycle that 
synthesizes mycolic acids (Banerjee et al., 1994). Interestingly, although both compounds are 
pro-drugs with chemical similarities their activation step is carried out by two different 
enzymes; while INH is activated by a catalase-peroxidase encoded by the katG gene, a flavin 
monooxygenase -ethA- activates ETH (Zhang et al., 1992; Heym et al., 1995,; Baulard et al., 
2000; Vannelli et al., 2002). Thus, most of the clinical isolates displaying resistance to each of 
those drugs are mutants defective in either KatG or EthA activity (Morlock et al., 2003). 
These reports generated two experimental approaches based on a rational design, leading to 
the design of new drugs affecting InhA. In the case of INH, a series of compounds showed 
promising activity against M. tuberculosis, inhibiting InhA and avoiding the activation step 
(Sullivan et al., 2006; Freundlich et al., 2009). Those compounds, derived from triclosan, a tri-
chlorynated aryl alkyl ether were subjected to a second round of structure improvement 
leading to molecules with the desired features of activity and no longer substrate of efflux 
pump systems (Tonge et al., 2007, am Ende et al., 2008). Similarly, research on the 
mechanism of action of ETH led to a smart way to improve its potency by increasing its rate 
of activation. To this end, the partnership between EthA and its repressor protein EthR, was 
used (Frenois et al., 2004; Weber et al., 2008). Thus, on the grounds that an inhibition of the 
activity of EthR would leave EthA free to act upon ETH, leading to its activation, a set of 
molecules was synthesized. The results demonstrated that by this approach, chemical 
“boosters” of ETH activity were obtained, increasing the therapeutic value of this molecule 
(Frenois et al., 2004; Willand et al., 2009) . 
Likewise, the elucidation of the mechanisms of action of both EMB and PZA, controversial 
in both cases, generated a great deal of interest on the possibility of identifying new drugs 
inhibiting the same targets than the lead compounds. In the case of EMB, an inhibitor of the 
synthesis of arabinogalactan (a key component of the cell envelope to which mycolic acids 
are covalently linked) (Takayama and Kilburn,1989; Khoo et al., 1996; Belanger et al., 1996; 
Telenti et al., 1997), the search for new anti-tubercular agents led to the identification of 
SQ109 (Protopopova et al., 2005; Jia et al., 2005) Unexpectedly, this compound, a diamine 
structurally related to EMB, did not affect arabinogalactan biosynthesis and its true target is 
still unknown. In spite of that, SQ109 is one of the very few compounds that is currently 
being tested in clinical trials. 
PZA, a pro-drug that is converted to the active Pyrazinoic acid (POA) through the action of 
an nicotinamidase/ pyrazinamidase (PncA), is still a very important component of the anti-
tubercular therapeutic scheme. This compound exerts a great activity at low pH, thus 
targeting the phagosomal bacillar population (Zhang et al., 1999). As described for other pro-
drugs, PZA lacks activity if mutations affecting PncA are generated. Similarly to what 
happened in the case of INH, the identification of the mechanism of action of PZA went 
through a period of uncertainty driven by the conflicting point of view of two laboratories, 
one supporting the idea of PZA inhibiting FASI (Zimhony et al., 2000), and the second 
sustaining the hypothesis that PZA acts through “in vivo” generation of Pyrazinoic acid 
(POA), a weak acid that kills M. tuberculosis due to its failure to cope with pH homeostasis 
efficiently Zhang et al., 1999; Zimhony et al., 2000). In agreement to that, while most of the M. 
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tuberculosis strains resistant to pyrazinamide are defective in PncA activity, susceptibility to 
POA is still observed. Although these different points of view did not hold back work on 
compounds that may mimic the activity of PZA, the fact is that only few derivatives have 
been proposed until now. Intriguingly some of those compounds, such as 5-chloro PZA, 
demonstrated a specific inhibition of FASI (Cynamon et al., 1998; Baughn et al., 2010), not 
shown by the parental PZA or by its derivative POA (Boshoff et al., 2002). Thus, the 
structure-activity relationship of those compounds seem to be more complex than firstly 
thought.  
Two more anti-tubercular drugs have been studied recently, both Isoxyl (ISO) and 
Thiacetazone (TAC) are thioureas, sharing the activation mechanism of ETH, thus being in 
fact pro-drugs that are activated by EthA (Kordulakova et al., 2007; Dover et al., 2007; 
Nishida and Ortiz de Montellano, 2011). Therefore their use is jeopardized by resistance to 
ETH since many clinical strains displaying that phenotype showed cross- resistance to the 
three drugs (Debarber et al., 2000). Both drugs alter the synthesis of fatty and mycolic acids 
but have different targets and mechanisms of action, so while ISO inhibits unsaturated fatty 
acid and mycolic acid synthesis, TAC seems to inhibit methyltransferases involved in 
mycolic acids modifications (Alhari et al., 2007). Several compounds have been made on the 
basis of the ISO and TAC scaffolds, with some showing good anti-tubercular activity 
(Bowhurt et al., 2006; Dover et al., 2007). In spite of the new information on these drugs, the 
fact that the molecular target(s) for each one has not been unequivocally identified yet, is 
delaying a rational approach to the design of analogues that would overcome both the need 
for an activator and eliminate the secondary effects of these two compounds. 
In summary, after over 50 years of use of drugs included in the clinical treatment of 
tuberculosis, the research on their mechanisms of actions and the mycobacterial mechanisms 
of resistance, produced the back-ground information needed to start drug development 
programs. Notwithstanding this fact, few programs have produced drugs that reached 
clinical testing, thus keeping a gap between the interest of pharmaceutical companies to 
invest in drug discovery programs and the social need to have new and better drugs to treat 
this devastating disease. 
3. Tug-of-war at the pharmaceutical industry: To discover and produce novel 
anti-tuberculosis agents or not 
The development of new anti-tubercular drugs has been slowed down by several obstacles 
of which we may mention three as the most important ones. In first place, the TB drug 
market is considered by pharmaceutical companies to be characterized by little profit 
opportunity or investment return. As a matter of fact, the cost of development of a new drug 
is estimated at $115 to $240 million US dollars (Gardner et al., 2006), thus to reach a 
reasonable level of profit, market prices of new drugs should be relatively high, contrasting 
with the current cost of the standard regimen, US $11 per patient (O´Brien and Nunn, 2001). 
A very comprehensive analysis of this matter has recently been discussed (Chang Blanc and 
Nunn, 2000). Importantly, government agencies are fully aware of the need to engage in the 
battle for the development of new anti-tubercular drugs. This awareness is shown by the 
several initiatives and programs established since 1994, such as the contracts awarded by the 
Tuberculosis Antimicrobial Acquisition and Coordinating Facility (TAACF) to centers of 
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remarkably high scientific level in the tuberculosis field, such as the Southern Research 
Institute, (SRI), the Hansen’s Disease Centers, and Colorado State University (Orme, 2001), 
the creation of the Tuberculosis Structural Genomics Consortium (Goulding, 2002), 
fundamental for the generation of a large set of data on putative mycobacterial targets 
amenable for drug design (Chim et al., 2011). Action TB, a multinational, interdisciplinary 
research initiative, was funded by the pharmaceutical company GlaxoSmithKline (GSK); 
although successful in promoting collaborations and translating research findings into drug 
screens and vaccine development, Action TB ended years ago. Various other research 
consortia are testing new drugs in preclinical and clinical trials, large funding agencies, such 
as the European & Developing Countries Clinical Trials Partnership (EDCTP) and the Bill & 
Melinda Gates Foundation are supporting these initiatives. The Global Alliance for TB Drug 
Development (TB Alliance), created in 2000 with support from the Rockefeller Foundation 
and the Gates Foundation (Pablos-Mendez, 2000; Gardner et al., 2005), has the goal of 
developing drugs that could shorten the treatment of active tuberculosis, being active on 
multi-drug resistant strains and on latent stages of the disease. 
In conclusion, although several major initiatives were launched some 20 years ago, with a 
considerable impact on the gathering of knowledge required to achieve the major goal of 
anti-tubercular drug development, pharmaceutical companies either had relatively low 
involvement or gave up after a few years. 
In second place, besides the profit considerations of drug making, anti-tubercular drug 
development faces a serious difficulty simply by the nature of the pathogen itself; as 
mentioned earlier, M. tuberculosis is present in sub-populations in the infected individual, 
each one in different cellular or extracellular locations . Moreover, not only the tubercle 
bacilli has the ability to enter a dormant state in which its metabolism diminishes to a 
minimum, but also can form biofilms (Wayne, 1994; Ojha, 2008). In both situations, the 
metabolic changes help the pathogen to evade the action of the anti-tubercular drugs. 
Ideally, clinical anti-tubercular regimes should kill both the rapidly growing mycobacteria 
and the persisting mycobacteria in lesions. The major problem is that the molecular 
mechanisms behind dormancy (characterized by a very low metabolic activity of the 
mycobacteria) and tolerance (drug-susceptible M. tuberculosis that survive in spite of 
continuous exposure to anti-tubercular drugs) are not yet fully deciphered (Zhang, 2004). 
Thus, from the point of view of the information available to rationally design new anti-
tubercular drugs, although more essential pathways are identified, they are not understood 
in full.  
The third challenge resides on the fact that there are currently no animal models that can be 
used with accuracy to test new anti-tubercular drugs and predict treatment duration 
(Druilhe et al., 2002; Mitchinson and Chang, 2009). At this point, the guinea pig model 
exceeds the mouse model since it displays pathology characteristics of the disease more 
closely resembling those of the infected human. In spite of that factor, the need to rely on the 
correct extrapolation of results from the animal model to the human led to an interest in 
developing a non-human primate animal model (Flynn et al., 2003; Flynn, 2006). It is not a 
minor point to state that this choice of an animal model to test the new anti-tubercular drugs 
implies a large difference in costs that has an obvious impact on the total investment 
required. All of these problems have already been pointed out by Lenaerts and co-workers 
(Lenaerts et al., 2005), who mention that from over 85,000 compounds tested for their anti-
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tubercular activity at Colorado State University (USA), only about 8% (7,500) showed 
reasonable activity as measured by Minimum Inhibitory Concentration (MIC), 700 had an 
acceptable selectivity index (reflecting the concentration required to inhibit M. tuberculosis 
vs. the concentration having toxicity on cultured eukaryotic cells), 11 showed “in vivo“ 
activity and only 5 compounds were considered potential leads and pursued further. 
Animal studies required 100– 150 mouse each, translating into a cost of US $ 400,000/study. 
Last but not least, the “gold standards” to evaluate efficacy of an anti-tubercular regimen in 
phase II (sputum culture conversion from positive to negative after two months of 
treatment) and III (relapse rate 2 years after completing clinical testing) are either 
controversial or lengthy processes that add to the paucity in the anti-tubercular drug 
development processes (van den Boogaard et al., 2009; Perrin et al., 2010). 
Thus, it is clear that anti-tubercular drug development is hampered by the lack of a small 
animal model that would be cost effective, display the characteristics of a natural infection 
to humans and produce an immune response upon infection comparable to that of humans.  
4. New molecules that may renew hopes of defeating M. tuberculosis 
It has briefly been described above how the information gathered on the mechanisms of 
action of drugs already in use helped to propose new molecules such as ENR inhibitors that 
do not require activation, boosters of ETH activity, and ETH analogues. Although those are 
promising steps forward in the race to prevail over the tubercle bacilli, there are several 
other compounds that are under clinical testing, some of which may reach the key stage of 
human use. As of May 2011, the Global Alliance for tuberculosis drug development shows 
in its webpage (http://www.tballiance.org/home/home.php) that three drugs are in 
clinical stages I and II: moxifloxacin (a fluoroquinolone), PA-824 (a nitropyran) and 
TMC207, a diarylquinolone. A second nitropyran, OPC-67683 is being studied in phase I 
clinical trials. With the exception of fluoroquinolones (since they were generated by 
programs not directed at the development of specific anti-tubercular drugs but aiming at 
general anti-bacterial drugs), these drugs will be briefly described below: 
Diarylquinolones. Diarylquinolines have been identified by broad screening of chemical 
libraries as having anti-tubercular activity (Diacon et al., 2009; Matteelli et al., 2010). The 
most active member of the set (TMC207, also called R 207910) is currently being evaluated in 
phase II clinical trials. The importance of this compound stems from its target, which is the 
essential mycobacterial ATP synthase enzyme (Koul et al., 2007; Haagsma et al., 2009). 
Because of that, it is not surprising that until now, there is no report of cross-resistance with 
available drugs and that the compound is equally efficient on MDR- M. tuberculosis strains. 
However, the fact that resistant mutants were isolated “in vitro”, having mutations in the 
atpE gene (encoding a subunit of ATP synthase) dampens to some extent the expectation of 
having a novel powerful drug (Koul et al., 2008). TCM 207 has a long half-life in plasma and 
so far, no drug-drug interactions with INH or PZA were detected. Unfortunately, plasma 
levels of TCM207 are reduced to 50% by RIF since it strongly induces a cytochrome P-450 
system (CYP3A4) that metabolizes TCM207, although a great deal of activity is still 
maintained. Thus, in this case, drug-drug interaction may not reach a relevance level that 
would avoid the use of these novel drugs. Addition of TCM207 to standard drug regimes 
improved efficacy of the treatment and specifically synergy with PZA was noticed in a 
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mouse model (Ibrahim et al., 2007; Ibrahim et al., 2009). Promising results were also observed 
in a guinea pig model with sterilization after six weeks of TCM207 monotherapy. Studies on 
human patients revealed good activity but due to the interaction with RIF, TCM207 activity 
is currently addressed in treatments not including this drug. 
Nitroimidazopyrans. The nitroimidazopyrans derive from bicyclic nitroimidazofurans that 
were initially developed for cancer chemotherapy (Stover et al., 2000; Denny and Palmer, 
2010). Their anti-tubercular activity against growing and dormant M. tuberculosis put two of 
these compounds (PA-824, a nitroimidazo-oxazine, and OPC-67683, a dihydroimidazo-
oxazole) into clinical testing (Lenaerts et al., 2005). There is a good deal of information on the 
mechanism of action of PA-824, which is -like several other anti-tubercular agents- a pro-
drug; in this case it is activated by the coupled system glucose-6-phosphate dehydrogenase 
(FDG1)- coenzyme F420 (Choi et al., 2001, Bashiri et al., 2008). Thus, mutations affecting the 
mycobacterial genes fbiA, fbiB, and fbiC cause a defect in coenzyme F420 synthesis and 
subsequently, resistance to PA-824 (Choi et al., 2001; Choi et al., 2002). Also, mutations in 
Rv3547, a deaza flavin dependent nitroreductase, have been described and associated to 
resistance to this compound (Manjunatha et al., 2006). Once activated, PA-824 exerts its 
activity shutting down the synthesis of proteins and cell wall lipids, although it seems that 
the main effect on non replicating bacilli is mediated by generation of reactive NO radical by 
reduction (Singh et al., 2008). As expected from its molecular features and activation step, 
PA-824 shows equal activity of drug susceptible and drug resistant strains with MICs in the 
sub-micromolar order. Importantly, there is no cross-resistance with the classical anti-
tubercular agents. The animal and human clinical studies performed recently asigned good 
pharmacokinetic features to PA-824: in mice it reached high serum concentrations rapidly, 
without any detectable undesired interaction with other anti-tubercular drugs 
(Neumrberger et al., 2006; Gisnberg et al., 2009). Its powerful bactericidal activity puts it in 
the same level of efficacy than INH or RIF, thus converting PA-824 in a surrogate candidate 
to replace RIF in those cases where the M. tuberculosis clinical isolate is resistant to RIF. 
Combined with moxifloxacin, PA-824 showed activity on mouse models of latent 
tuberculosis, which makes this compound a very attractive candidate to treat human latent 
tuberculosis (Singh et al., 2008). In spite of those valuable features, PA-824 failed in 
shortening treatment times, and although it did not display any antagonism, it did not show 
any synergy. 
The second nitropyran, OPC-67683 is also a pro-drug that acts by inhibiting the synthesis of 
two families (methoxy- and keto-) of mycolic acids, essential components of the 
mycobacterial cell wall (Sasaki et al., 2006; Matsumoto et al., 2006). Interestingly, the 
mycobaterial mechanism of resistance to PA-824 is also used to confer resistance to OPC-
67683, thus mutations in the M. tuberculosis Rv3547 gene are also behind the resistance to 
this new inhibitor. There is no drug-drug interaction with any of the currently used anti-
tubercular drugs and recent studies indicate that OPC-67683 has good intracellular killing 
ability and high sterilizing activity even on drug tolerant (persistant) sub-populations of  
M. tuberculosis (Saliu et al., 2007). These features, along with its lack of interactions with the 
liver microsomal enzymes (thus not being affected by them) strenghten the chances of this 
molecule to be added to the therapeutic regime. As a disadvantage, its Early Bactericidal 
Activity is low although along the treatment time this compound exerts a high sterilizing 
activity (Saliu et al., 2007). There is still a long way to go to reach that point and clearly, more 
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evaluation of its activity, adverse effects and drug formulation is required. Nonetheless, 
OPC- 67683 remains as a new choice to treat MDRTb and XDR-TB infections, targeting at the 
same time the dormant and persistant sub-populations. 
Other drugs under study. This brief description is by no means complete and it does not 
intend to describe the whole set of compounds that are being studied by different public 
and private ventures. It only presents those compounds which are already part of clinical 
trials and thus, are the most promising candidates to join the therapeutic anti-tubercular 
regimes. Amongst several other molecules which are under vigorous studies now, we may 
cite proposed inhibitors active on the FASII dehydratase (i.e. NAS 91 and derivatives) 
(Bhowrut et al., 2008), inhibitors of FtsZ, a critical protein involved in cell division (Huang et 
al., 2007; Slayden and Belisle, 2009; Kumar et al., 2010), inhibitors of AccD6, an essential 
acetyl-CoA carboxylase necessary for the synthesis of malonyl-CoA required for fatty acid 
biosynthesis (Lin et al., 2006; Kurth et al., 2009), and compounds such as 1,3-benzothiazin-4-
one (inhibitor of the enzyme decaprenylphosphoryl--d-ribose 2'-epimerase involved in cell 
wall arabinans) (Makarov et al., 2009; Manina et al., 2010), a serious contender to reach the 
podium of novel anti-tubercular medicine. Finally, clinical studies on other novel 
compounds displaying anti-mycobacterial activity are being pursued at different pace, there 
is not enough information available to assess their possible impact; like in the case of SQ109 
(Protopopova et al., 2005; Jia et al., 2005), and pyrrol derivatives such as LL-3858 (Ginsberg, 
2010). 
5. Available drugs that deserve an opportunity 
In the current context of drug development, when the quest is so time consuming and so 
demanding in terms of the funds required, it brings a beacon of light and hope the fact that 
there are some drugs with proven activity against M. tuberculosis that have been in clinical 
use for long time. Although those compounds are effective against different non bacterial 
infections and even on non infectious diseases, the strength of the information gathered 
lately, underscoring the potency of their effect on the tubercle bacilli is impossible to ignore. 
The compounds I am referring to are a- the efflux pumps inhibitors, verapamil and 
reserpine; b- the antifungal azoles, and c- the neuroleptics phenothiazines. A brief overview 
of each of these compounds is given below. 
5.1 Efflux pumps in M. tuberculosis, their role in tolerance to drugs and a simple way 
to prevail over them 
The amazing complexity of mycobacteria reveals at least two mechanisms to undermine the 
power of anti-mycobacterial drugs, one is the intrinsic resistance presented by its cell wall 
envelope, characterized by a very low permeability (Nikaido and Jarlier, 1991; Liu et al., 
1996); the second one is the presence of several systems that actively pump out drugs (De 
Rossi et al., 2002; Viveiros et al., 2003).  
Bacterial drug efflux pumps are classified into five groups, two of them, the ATP-binding 
cassette superfamily and the major facilitator superfamily, contain a large number of 
members while the other three (the small multidrug resistance family, the resistance-
nodulation-cell division family and the multidrug and toxic compounds family) although 
increasing, are less populated. It is not the subject of this manuscript to dissect the molecular 
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biology of those families, but it is one of its goals to mention the role of all those families that 
are represented in the M. tuberculosis genome (as well as in other mycobacterial genomes) in 
the drug discovery process. 
The overall resistance to the drugs that have been part of the classical anti-tubercular therapy, 
share a common characteristic, the existence of a variable percentage of resistant M. tuberculosis 
strains that do not contain mutations neither in the genes identified as molecular targets nor in 
the genes encoding the activators in the case of pro-drugs; so, while mutations in katG and 
ethA (encoding the activator enzymes) and inhA (encoding the target enzyme) cover most of 
the strains resistant to INH and ETH described in the literature, there is a percentage of those 
strains that does not show any mutations in the mentioned genes. The body of evidence 
gathered over the last years, uncovering the role of other genes such as ndh (encoding the 
NADH dehydrogenase) (Miesel et al., 1998; Vilcheze et al., 2005) and mshA, mshB and mshC 
(involved in the biosynthesis of mycothiol) in the resistance to INH and ETH in M. tuberculosis 
and M. smegmatis (Vilcheze et al., 2008, 2011; Xhu et al., 2011) cannot account for a fraction of 
resistant strains that do not have any mutation in those genes. A comparable situation is found 
in the case of the resistance to PZA, another pro-drug which has pcnA as its activator. 
Mutations in this gene, encoding the amidase required to produce the active drug, Pyrazinoic 
acid (POA), accounts for a large fraction of the resistance in M. tuberculosis (Jureen et al., 2008). 
In spite of that, PZA resistant strains without mutation in pcnA have been reported (Raynaud 
et al., 1999). Furthermore, the identification of mmpL7, a lipid transporter, as an efflux pump 
capable of mediating resistance to INH puts forth the role of efflux pumps in the resistance to 
drugs in mycobacteria (Pasca et al., 2005). Thus, the resistance to several anti-bacterial 
(including Streptomycin, Aminoglycosides, Fluoroquinolones, Tetracycline, Rifampicin) and 
anti-tubercular drugs (Ethionamide, Isoniazid, Ethambutol) has been associated to the efflux 
pumps encoded in the mycobacterial genome. This is not surprising considering the number of 
genes encoding efflux pumps in mycobacteria, some of them, such as mmpL7, having a 
physiological role unrelated to antibiotic elimination from the cytoplasm. A relevant point is 
that although some efflux pumps have been characterized, there are few publications 
reporting a comprehensive testing of anti-bacterial and anti-tubercular drugs on efflux pump 
gene expression (Jiang et al., 2008; Gupta et al., 2010), so it is possible that any given pump may 
be involved in resistance to drugs that have not been tested. A second important point is that a 
systematic deletion of efflux pump genes in M. tuberculosis along with examination of the level 
of resistance to tubercular inhibitors has not yet been accomplished. This would be the only 
method that would clearly correlate drug resistance to each efflux pump. Finally, in several 
cases, the identification of M. tuberculosis efflux pumps stems from their molecular cloning and 
expression in a surrogate model (M. smegmatis) which, although similar to M. tuberculosis has 
intriguing differences in the number and nature of these pumps (Liu et al., 1996; Li et al., 2004). 
An example of that is the existence of LfrA, that eliminates Fluoroquinolones from the 
M.smegmatis cytoplasm (Sander et al., 2000). The lfrA gene is not present in the M. tuberculosis 
chromosome; in spite of that, two different systems, one encoded by Rv1634 (De Rossi et al., 
2006), and the second by the operon formed by Rv2686c-Rv2687c-Rv2688c, take part in the 
elimination of Fluoroquinolones in this pathogen (Pasca et al., 2004). 
According to recent literature, there are 15 genes (named mmpL and mmpS) present in the M. 
tuberculosis genome, that are classified as members of the RND family (De Rossi et al., 2006). 
In order to assess the role of those proteins in drug resistance, Domenech et al. constructed 
deletion mutants in each one of the 11 mmpL genes present in the M. tuberculosis genome 
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(Domenech et al., 2005) Interestingly, a previous report by Pasca et al. pointed out that over-
expression of mmpL7 conferred INH resistance to M. smegmatis, a phenotype that decreased 
upon addition of the efflux pump inhibitors, carbonyl cyanide m-chlorophenylhydrazone 
(CCCP), ortho-vanadate, reserpine, and verapamil (Choudhuri et al., 1999, Pasca et al., 2005). 
In spite of this evidence, Domenech et al. reported that the deletion of this gene failed to 
increase the susceptibility to this anti-tubercular drug. Moreover, none of the mmpL genes 
seemed to participate in resistance to drugs, as no compelling decrease in the MICs was 
observed in the M. tuberculosis mutants lacking these genes (Domenech et al., 2005). Current 
evidence favours the idea that mmpL proteins are devoted to the transport of complex lipid 
molecules (Camacho et al., 2001; Converse et al., 2003; Jain and Cox, 2005), thus it is possible 
that because of that function, over-expression of some of these genes (such as mmpL7) may 
affect biophysical characteristics of the cell envelope, leading to a secondary phenotype of 
mild resistance to some anti-tubercular drugs. 
Heavily represented in the mycobacterial genome, ABC transporters account for 2,5% of the 
chromosomal genes (Braibant et al., 2000)(7). Bioinformatic analysis revealed 25 complete 
ABC transporters for which potential substrates could be postulated in many cases, leading 
to the prediction of 9 importers and 16 extruders. Comparison to transporter sub-families in 
other bacteria allowed for the finding of nine of them in M. tuberculosis, of those, three were 
linked to drug transport and one of them was postulated to encode three macrolide 
transporters members (Rv1473, Rv2477 and Rv1667c-Rv1668c) (Braibant et al., 2000). A 
second sub-family grouped four transporters similar to multidrug resistance (MDR) 
proteins of eukaryotes and prokaryotes. Three of them are encoded by two genes arranged 
in tandem (Rv1273c-Rv1272c and Rv1348-Rv1349) while the remaining two transporters are 
encoded by single genes (Rv0194 and Rv1819). Lastly, the third sub-family includes six 
transporters with different gene organization, three containing three genes clustered in the 
genome (drrA-drrB-drrC, Rv1458c-Rv1457c-Rv1456c, Rv2688c-Rv2687c-Rv2686c), two 
formed by two genes (Rv1218c- Rv1217c and Rv1687c- Rv1686c) and one by a single gene 
(Rv1747) (Braibant et al., 2000). The identification of an ABC transporter encoded in the Rv 
2686c-2687c-2688 operon that confers resistance to fluoroquinolones led to explore its 
susceptibility to known inhibitors of transporters systems. Three of the compounds that 
have been mostly used in this analysis are CCCP (a Proton Motif Force uncoupler), 
reserpine (an inhibitor of ATP dependent efflux systems) and verapamil (an inhibitor of the 
mammalian P-glycoprotein drug transporter).  
Like the ABC transporter family, the MSF family is also a large one; early work by de Rossi 
et al.. postulated through bioinformatics, the presence of sixteen candidate genes (Rv3239c, 
Rv3728, Rv2846c, Rv1877, Rv2333c, Rv2459, Rv1410c, Rv1250, Rv1258c, Rv0783c, Rv1634, 
Rv0849 Rv0191,Rv0037c, Rv2456c, and Rv2994) (De Rossi et al.,2002), although cloning and 
expression in the surrogate M. smegmatis of ORFs Rv0037c, Rv0783c, Rv0849, Rv1250, 
Rv1877, Rv2333c, Rv2459, Rv2994, and Rv3239c failed to confer significant levels of 
resistance to a panel of drugs. Surprisingly, expression of the Rv2686c-Rv2687c-Rv2688c 
operon, not included in the list mentioned above, conferred resistance to fluoroquinolones 
in M. tuberculosis (Pasca et al., 2004). It is important to mention that a member of this list, 
Rv1410c (also known as P55 (Silva et al., 2001)), confers resistance to gentamicin, tetracyclin 
and streptomycin when over-expressed and that its function is abrogated by the addition of 
the efflux pump inhibitors verapamil and reserpine. In agreement with the proposed role, 
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work carried out by Ramon-García et al. showed that the deletion of Rv1410c caused 
increased susceptibility to rifampicin, novobiocin, vancomycin and econazole (Ramon-
Garcia et al., 2009). Importantly, those authors found out that the M. tuberculosis P55 knock-
out mutant became more susceptible to oxidative stress and failed to form normal size 
colonies, stressing the key role of this protein in the proper assembly of the cell envelope. 
These results were very recently confirmed by Bianco et al.. who demonstrated that the 
LprG-P55 operon is required for proper cell wall assembly (Bianco et al., 2011). 
Intriguingly, only one gene (mmr) belonging to the SMR (Small Multidrug Resistance 
Family) family and related to drug efflux (in this case Erythromicin) has been located in the 
M. tuberculosis chromosome (De Rossi et al., 1998).  
Finally, to add more complexity to the already intricate scenario, Stephan et al. reported that 
the loss of MspA, a major porin of M. smegmatis determined an increase in the resistance to 
large antibiotic molecules such as rifampicin, vancomycin and erythromicin, results that 
support the hypothesis that the loss of this porin reduces the permeability of the 
mycobacterial cell envelope (Stephan et al., 2004). 
Thus, although still partial, the knowledge gathered over the last years on the mycobacterial 
efflux systems points out that even being accessories to the main mechanisms of resistance, 
efflux pumps play a role in resistance to anti-tubercular drugs, several of those pumps are 
inhibited by reserpine and/or verapamil, drugs with an extensive history of use in human 
patients. With that information, novel strategies based on using the mentioned inhibitors 
associated to anti-tubercular drugs would have been a logic continuation at the level of basic 
research as well as of clinical trials. Thus, it is surprising that no studies on this topic were 
carried out until very recently when a paper by Ramakrishnan´s group pointed out that the 
mycobacterial efflux pumps are responsible in part for the drug tolerance in a zebrafish 
model of infection (Adams et al., 2011). One of such efflux pumps, encoded by the gene 
Rv1258c, is induced upon macrophage infection, leading to a RIF tolerance phenotype. A 
mutant strain carrying a transposon insertion in that gene displayed susceptibility to RIF in 
a macrophage infection model. Verapamil and reserpine are anti-hypertensive drugs that 
can destroy the activity of mamalian and bacterial efflux pumps, an unexpected side effect 
(so far without a clear mechanism of action) to their usual clinical use. The treatment of M. 
tuberculosis–infected macrophages with reserpine abolished the tolerance to RIF (Adams et 
al., 2011). Thus even when not every M. tuberculosis efflux pump system is inhibited by 
reserpine or by verapamil, the use of those compounds and/or any other new inhibitor of 
efflux pumps may decrease the tolerance to drugs, and shorten the treatment. Although 
more work is required to study drug-drug interactions and determine the optimal dosage of 
these anti-hypertensive drugs, it seems to be a promising and fresh starting point. 
5.2 Azoles, antifungal drugs with a taste for tuberculosis 
The sequencing of the genome of M. tuberculosis H37Rv was source of numerous surprises: 
one of which was the identification of a set of 20 genes enconding Cytochrome P450 
(CytP450) dehydrogenases (Cole et al., 1998). This large number is not exclusive of  
M. tuberculosis as there is a comparable number both in related slow growers such as M. 
bovis, as well as in the saprophytic fast-grower M. smegmatis that encodes 26 CytP450 genes. 
A similar collection is present in non mycobacterial Actinomycetes such as Streptomyces; 
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interestingly, M. leprae, the pathogenic mycobacterium that excelled in genome decay, has 
only one cyp gene (Cole et al., 2001). Bioinformatic analysis also showed the presence of four 
genes (CYP121A1, CYP128A1, CYP141A1, CYP135A1) that seem to be unique to the  
M. tuberculosis complex.  
The function of these enzymes is complex and versatile. The typical P450 reaction is a mono-
oxygenation in which one of the oxygen atoms of molecular oxygen is inserted into an 
organic substrate while the second oxygen atom undergoes reduction to water. In spite of 
that, there are other P450- catalyzed reactions, including heteroatom oxidation and 
epoxidation. The observation that the M. tuberculosis was unusually rich in genes encoding 
enzymes that would be involved in fatty acid modification and degradation, coexisting with 
the large repertoire of CYP450 dehydrogenases led researchers to hypothesize that at least 
some of these would be involved in fatty acid metabolism. However, only one, CYP51B1, 
could be classified considering its important sequence homology to eukaryotic CYP51 
enzymes as well as because of its sterol 14-demethylase catalytic activity. Curiously, 
excepting CYP135A1 and CYP135B1, which show 40% identity, the remaining  
M. tuberculosis P450 enzymes display much less similarity (around 30%). In agreement with 
the idea explicited above, several of the M. tuberculosis P450 enzymes have similarities with 
isoprenoid and fatty acid hydroxylases although functional assays must be performed to 
confirm the bioinformatics analysis. 
A genomic approach based in the analysis of transposon insertion sites (TRASH) suggested 
that only one gene (cyp128A1) was essential for “in vitro growth” (Sassetti et al., 2003), result 
that was not confirmed by a second independent analysis (Lamichhane et al., 2003). 
However, evaluation of the M. tuberculosis transposon mutants able to replicate in a mouse 
infection model picked cyp125A1 as the only cyp gene needed for a successful mycobacterial 
propagation (Sassetti et al., 2001). Although cyp121A was placed in a list of essential genes 
by specific gene deletion these results were opposed by reports indicating that several 
clinical isolates were mutated in cyp121A (Tsolaki et al., 2004) The controversy on the results 
obtained through those approaches raised again when it was reported that none of the cyp 
genes was essential for growth inside macrophages. Nonetheless, transposon insertions in 
six cyp genes (cyp121A1, cyp123A1, cyp125A1, cyp127A1 cyp128A1 and cyp137A1) have 
variable impact on mycobacterial attenuation. Unfortunately, the substrates for these 
enzymes have been identified in very few cases; in example, the analysis of CYP121A 
revealed that it intervenes in the synthesis of a L-tyrosine-L-tyrosine cyclic dipeptide of 
unknown function. A second case is CYP51B, that shows homology to and activity of 14-
sterol demethylases, an intriguing observation considering that M. tuberculosis does not have 
a complete sterol biosynthetic pathway in which those enzymes are found. Both CYP125A 
and CYP128A1 have also been associated to mycobacterial metabolic processes, the first one 
taking part in the degradation of host cholesterol used by M. tuberculosis during infection, 
and the second one hydroxylating an isoprene unit in the synthesis of a mycobacterial 
sulfolipid (Rengarajan et al., 2005; Holsclaw et al., 2008). Again, opposing results have been 
produced, as this sulfolipid is critical for virulence but not for “in vitro” growth in spite of 
results from TRASH experiments that indicated an essential role for growth under 
laboratory conditions (Sassetti et al., 2003)  
Less characterized, other CYPs such as CYP123A1 seem to be under the control of the PhoP- 
PhoR operon, a two component system which is strongly involved in virulence to the point 
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that a mutation in it is the basis of the lack of virulence of M. tuberculosis strain H37Ra. The 
remaining CYPs have not been studied to a point at which significant conclusions may be 
drawn. Most of the inferences come from analysis of gene location and the nature of nearby 
genes, evaluation of essentiality by TRASH analysis (although for some genes these results 
did not match the ones produced by specific gene knock-out), distribution through the 
mycobacterial genus and other actinomycetes, and biochemical studies.   
Regardless of the level of information on mycobacterial CYPs, there is interest on them after 
the report that azoles, drugs with anti-fungal activity and decades of clinical use, are active 
on M. tuberculosis and other mycobacteria. During analysis of drug able targets in M. 
tuberculosis, six of the top eight genes picked up were the P450 enzymes CYP123A1, 
CYP124A1, CYP125A1, CYP130A1, CYP140A1 and CYP142A1; moreover, CYP126A1, 
CYP128A1 and CYP51B1, were placed within the top candidate enzymes, thus nine out of 20 
M. tuberculosis Cyt P450 enzymes were positioned at the top of a list of drug targets (Aguero 
et al., 2008). It is reasonable to expect that there will be a great deal of research on this 
subject.  
As was mentioned above, the discovery of CYP51B1, a M. tuberculosis enzyme homologous 
to the fungal sterol 14-demethylase led to the tempting hypothesis that antifungal azole 
compounds might also target CYP51B1 and other P450 enzymes with lethal effects for the 
pathogen. In a short time, the anti-mycobacterial activity on M. tuberculosis was 
demonstrated on “in vitro”, “ex-vivo” and “in vivo” assays (Ahmad et al., 2005; Ahmad et 
al., 2006 a,b,c) (3-6). Moreover, azoles were active on M. smegmatis, with loss of 
glycopeptidolipid (GPLs) biosynthesis (Burguiere et al., 2005. Unfortunately there are 
several inconsistent issues in those results: in first place, GLPs are not essential components 
of M. smegmatis as knock-out of the pathway render viable cells with an altered envelope 
(Deshayes et al., 2010). In second place, GPLs are not present in M. tuberculosis suggesting 
different target(s); in last place Fluconazole, an azole with the highest binding to CYP121A1 
is inactive on M. tuberculosis although it is very active on fungi. More conflicting data 
suggesting target(s) other than CYPs for azole drugs stem from microarray analysis 
comparing a wild-type strain to a bifonazole-resistant strain; the study showed no induction 
of any CYP gene upon treatment with bifonazole (Milano et al., 2009). Instead, three genes 
(Rv0678, Rv0677c and Rv0676c), showed higher levels of expression in the Bifonazole 
mutant compared to the wild-type strain. Not surprisingly, Rv0677c and Rv0676c encode 
the membrane proteins MmpS5 and MmpL5, predicted to be RND family of transporters, 
and therefore, very likely involved in mediating resistance to azoles by efflux of the drug 
(Milano et al., 2009). In agreement with those results, Milano et al. confirmed the 
involvement of efflux pumps in the resistance to azoles by selecting and sequencing azole-
resistant mutants of M. tuberculosis and M. bovis var BCG; their results proved that over-
expression of mmpS5-mmpL5 were responsible for the resistance phenotype. This pump was 
susceptible to CCCP, as this treatmente reduced the resistance to azole drugs back to wild-
type levels. Moreover, sequencing of cyp encoding genes failed to show any mutation in a 
M. bovis var BCG mutant resistant to the azole drug bifonazole. In summary, there is no 
proof of a direct link between azole drugs and the inhibition of CYPs as a mechanism of 
action. Nonetheless, it is possible that additive inhibition of those non-essential CYP targets 
may bring the accumulation of growth inhibitory intermediates and /or depletion of cellular 
metabolites of importance. 
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Although azoles have the great advantage of a large body of information in humans, they 
also have the disadvantage of their low oral bioavailability, generating a proposal of their 
use in encapsulated form. They also have a noticeable impact on human metabolism 
through the inhibition of the liver P450 enzymes, thus drug-drug interactions and changes 
in pharmacokinetics and metabolization of drugs are expected. 
In summary, having a relatively high number of azole compounds with therapeutic use in 
humans, the fact that there is no known target(s) and thus mechanism(s) of action for those 
drugs, dims the initially bright possibility of adding them to the anti-tubercular drug 
portfolio. The simplicity and relative low cost of the currently existing whole genome 
sequencing techniques should be used to address those points by analyzing azole-resistant 
M. tuberculosis mutants, most likely selecting them in the presence of efflux pump inhibitors.  
5.3 The thioridazine story (or how perseverance is also an essential tool for  
anti-tubercular drug discovery) 
In the quest for novel drugs with improved killing activity against M. tuberculosis, a number 
of non-antibiotic molecules have been tested; among them, some compounds that displayed 
a surprisingly high killing activity belonged to the family of anti-psychotic drugs. Original 
work carried out by Ehrlich at the end of the 19th. century led to the discovery of the anti-
bacterial and neuroleptic activities of methylene blue, a phenothiazine; later on, its activity 
on the central nervous system was privileged, leading to the synthesis of chlorpromazine as 
reviewed by Kristiansen, 1989. Paradoxically, anti-bacterial activity of this compound was 
again proven over the following years but left aside due to the large number of antibiotic 
options that were marketed at that time as well as due to the strong toxic side effects 
displayed in large treatments. Although the introduction of the less toxic compounds 
thioridazine and promazine decreased the toxicity problem, there was no interest in 
applying these kind of molecules to the treatment of bacterial infections. The emergence of 
multi-drug resistant M. tuberculosis strains triggered an urgent search for new compounds 
that could kill those strains efficiently. Thus, research on phenothiazines was embraced by a 
few investigators that were convinced of the possible uses of that family of drugs (Amaral 
and Kristiansen, 2000; Kristiansen and Amaral, 1997; Viveiros and Amaral, 2001; Amaral et 
al., 2004). Even when the concentration of phenothiazines needed to kill M. tuberculosis “in 
vitro” were several times higher than the one reached in plasma of patients (20 g/ml vs 0.4 
g/ml), the observation that these compounds were concentrated by macrophages, 
suggested that a balance could be obtained between the intracellular concentration reached 
and the concentration required to destroy M. tuberculosis phagocytosed by the macrophages 
(Crowle et al., 1992; Ordway et al., 2003). It was indeed so, as proven by Crowle´s group, and 
that helped to potentiate the research of a few groups that enthusiastically showed 
thioridazine as the phenothiazine with the highest killing effect and the lowest toxicity 
(Amaral et al., 1996, 2008; Viveiros et al., 2005; Crowle et al., 1992). Moreover, it was clearly 
demostrated that this compound was active on MDR-TB and XDR-TB residing inside the 
macrophages, needing to be present at such a low concentration (0.1g/ml) that it was 
devoid of toxicity. The obvious disadvantage of the requirement for a much higher 
concentration of thioridazine to kill extracellular M. tuberculosis when lung damage is 
produced may be easily compensated by the use of other drugs much more active on those 
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extracellular bacilli. Even when the infecting strain is a MDR-TB or a XDR-TB strain, 
thioridazine may be teamed up with some of the novel drugs described in previous sections, 
drugs that either overcome the resistance mechanisms or target totally new targets and 
pathways. It is highly promising that Martins et al. has published an article describing the 
action of several derivatives of thioridazine showing extreme ability to kill intracellular M. 
tuberculosis at low dose and needing only one day to do so, contrasting with the three days 
required for the same level of action by thioridazine (Martins et al., 2007). Almost 
simultaneously, Bate et al. described novel synthetic derivatives of promethazine and 
promazine; those compounds were not only effective on actively growing M. tuberculosis but 
also on latent M. tuberculosis (Bate et al., 2007).  
In terms of the identification of the molecular mechanisms of action and mycobacterial 
components targeted by phenothiazines, its has been shown time ago, that these compounds 
can inhibit efflux pumps at concentrations lower than those required to inhibit 
mycobacterial growth (Amaral et al., 2007, 2008, 2010); one of such inhibited efflux 
mechanisms may lead to the build up of calcium and potassium ions in the phagosome, 
reverting the mycobacterial driven block to the action of hydrolyases and other calcium-
dependent macrophage mechanisms which in turn may destroy the bacilli (Martins et al., 
2008, 2009)). Rubin´s group demonstrated the inhibition of the type II NADH-menaquinone 
oxidoreductase (NDH-2), an essential enzyme of the M. tuberculosis respiratory chain, by 
thioridazine and derivatives; its inhibition leads to a blockade in the electron chain 
transport, thus it is most likely the most important target for these compounds (Weinstein et 
al., 2005). Ndh-2 is the only NADH dehydrogenase enzyme expressed in this pathogen, 
importantly it is absent in humans that rely on the type 1 Ndh enzyme. Biochemical, 
transcriptional and genetic analysis supports the vital role played by Ndh-2 (Yano et al., 
2006). At the light of the published information regarding the multiple targets for 
thioridazine, the synthesis of less toxic derivatives and the fact that these compounds are 
concentrated in the macrophages, it is reasonable to consider these molecules as promising 
compounds that would become not only drugs by themselves but helpers to other drugs 
due to the inhibition of the mycobacterial efflux pumps.  
As has been stated by Amaral et al., early work from Kristiansen (Kristiansen and Amaral, 
1997) postulated that neuroleptics such as thioridazine and chlorpromazine, displayed anti-
bacterial activity by affecting an unknown cell membrane process. Kristiansen went even 
further coining in 1990 the term “non-antibiotic” to define “medicinal compounds that are 
used for the treatment of non-infectious pathologies and which also have anti-microbial 
activity”. With tremendous perseverance, Amaral and co-workers have been supporting 
neuroleptics as drugs that may be used for compasionate reasons in cases of human 
tuberculosis that are of bad prognosis and difficult treatment due to drug resistance. These 
researchers insisted for more than ten years that the neuroleptics described above had 
enough activity per se and as “helpers” to be included in the clinical treatment of 
tuberculosis (Amaral et al., 2004, 2007a, 2007b, 2008, 2010, Martins et al., 2007a,b, 2008; 2009; 
van Ingen et al., 2009, Viveiros and Amaral, 2001; Viveiros et al., 2003, 2005, 2010). 
Notwithstanding the body of evidence gathered by them, there has been little receptiveness 
by the pharmaceutical industry and public health organisms, leading Amaral to put out his 
frustration through a paper bearing a very challenging title: “Thioridazine cures extensively 
drug-resistant tuberculosis (XDR-TB) and the need for global trials is now!” (Amaral et al., 
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2010). Furthermore, their latest work in association with the groups of Dick van Soolingen 
and Rogelio Hernandez- Pando demonstrated the effectiveness of thioridazine in a mouse 
model of multi-drug resistant M. tuberculosis infection (van Soolingen et al., 2010). Since as 
has been put forward by Amaral and co-workers, thioridazine and similar molecules 
already in the market may be described as antipsychotic drugs that are still protected by 
patents as “new use” (Amaral and Molnar, 2010; Dutta et al., 2011), there are good chances 
that the actors involved at both public health organizations and private partners will take 
this matter to a step where these neuroleptics are tested throughout the world. 
6. The choice: Broad screening of chemical libraries or rational design based 
on molecular targets 
Along the sections of this chapter I have briefly described the mechanisms of action of 
several drugs that inhibit growth or kill M. tuberculosis. Two opposite approaches for the 
goal of obtaining new anti-tubercular medicines are based a- on the biological screening of 
large size chemical libraries (Maddry et al., 2009; Anathan et al., 2009) and b- on structure 
based design by means of molecular modelling of chemical compounds on the structure of 
the enzyme under study (Arcus et al., 2006). In between these two options, a third one is to 
produce derivatives of compounds with known activity and mechanisms of action (such as 
ISO) but without having structural information of the target enzyme. From the specific anti-
tubercular compounds currently used in clinical practice, INH, ETH and PZA have been 
used as scaffolds for rational drug design. On the basis of the understanding of the nature of 
the lethal event, different approaches were taken towards that end; i.e. through an increased 
conversion of the pro-drug to the active drug (ETH boosters), through the inhibition of the 
identified target by a different molecule not requiring activation (aryl alkyl ethers inhibitors 
of InhA) or modification of the lead compound (PZA and 5-Cl PZA). The identification of 
essential mycobacterial enzymes and their intensive characterization at the biochemical and 
structural level led to propose compounds with activity in the case of cell division (FtsZ) 
and fatty acid biosynthesis (AccD6). Notwithstanding that, all the compounds that are 
under phase I and II clinical testing (PA-824, TMC207, LL3858, SQ109 and OPC-67683) have 
been identified by broad screening (Spiegelman, 2007), although in the case of one of them, 
OPC-67683, the search was oriented to compounds with a defined mode of action, the 
inhibition of synthesis of mycolic acid. 
So, although logic should have tip the balance towards the utilization of structure-based 
methods, there is a bias towards screening of libraries of chemical compounds by high 
throughput methods looking for whole-cell or “in vitro” enzyme inhibition.  
7. Summary 
There are several reviews in the literature that describe the mechanisms of action of anti-
tubercular drugs currently in clinical use, and also a large number of publications 
summarizing the quest for new drugs and the nature of the novel compounds that may be 
added to the anti-tubercular treatment in short time. The objective of this review is different 
from that, and although I have offered a brief account of the recent developments in the 
field, commenting on the two main approaches (broad screening vs structure-based design) 
for anti-tubercular drug development, I have chosen to focus on few compounds to 
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demonstrate that there are drugs already produced at pharmaceutical industry levels 
(namely azole drugs, verapamil, reserpine, and thioridazine) with a large history of use in 
humans –therefore providing rich information on adverse effects, pharmacokinetics, 
pharmacology, etc- which are effective on M. tuberculosis, not only on pan-susceptible strains 
but also on MDR-TB as well as on XDR-TB strains; moreover, the effect of some of those 
drugs reaches as far as the latent population of this pathogen. The fact that the mentioned 
compounds have already been approved for human use by regulatory agencies shortens the 
time for the evaluation of their new uses as many aspects have already been addressed. 
Thus we have a unique opportunity to seize, concentrating effort at academic laboratories to 
increase our understanding on mechanisms of action of these compounds as well as learning 
about the ensuing mechanisms of resistance in mycobacteria, testing drug –drug interactions 
and generating the comprehensive body of knowledge needed to incorporate these drugs to 
the anti-tubercular portfolio. On a personal basis, I strongly believe that coordinated effort 
on those compounds by research groups may produce at last the addition of the mentioned 
drugs to clinical treatment, helping to stop the spreading of human tuberculosis. It is 
possible that by taking a bold decision on those issues, we will reach our El Dorado: new 
drugs to defeat tuberculosis.  
8. Acknowledgements 
HRM is a carreer member of Consejo de Investigaciones, UNR, Argentina. This work was 
funded by grants from ANPCyT and UNR. 
9. References 
Adams, K. N., K. Takaki, L. E. Connolly, H. Wiedenhoft, K. Winglee, O. Humbert, P. H. 
Edelstein, C. L. Cosma, and L. Ramakrishnan. 2011. Drug tolerance in replicating 
mycobacteria mediated by a macrophage-induced efflux mechanism. Cell 145:39-
53. 
Aguero, F., B. Al-Lazikani, M. Aslett, M. Berriman, F. S. Buckner, R. K. Campbell, S. 
Carmona, I. M. Carruthers, A. W. Chan, F. Chen, G. J. Crowther, M. A. Doyle, C. 
Hertz-Fowler, A. L. Hopkins, G. McAllister, S. Nwaka, J. P. Overington, A. Pain, G. 
V. Paolini, U. Pieper, S. A. Ralph, A. Riechers, D. S. Roos, A. Sali, D. Shanmugam, 
T. Suzuki, W. C. Van Voorhis, and C. L. Verlinde. 2008. Genomic-scale 
prioritization of drug targets: the TDR Targets database. Nat. Rev. Drug Discov. 
7:900-907. 
Ahmad, Z., S. Sharma, and G. K. Khuller. 2005. In vitro and ex vivo antimycobacterial 
potential of azole drugs against Mycobacterium tuberculosis H37Rv. FEMS Microbiol. 
Lett. 251:19-22. 
Ahmad, Z., S. Sharma, and G. K. Khuller. 2006. Azole antifungals as novel chemotherapeutic 
agents against murine tuberculosis. FEMS Microbiol. Lett. 261:181-186. 
Ahmad, Z., S. Sharma, and G. K. Khuller. 2006. The potential of azole antifungals against 
latent/persistent tuberculosis. FEMS Microbiol. Lett. 258:200-203. 
Ahmad, Z., S. Sharma, G. K. Khuller, P. Singh, J. Faujdar, and V. M. Katoch. 2006. 
Antimycobacterial activity of econazole against multidrug-resistant strains of 
Mycobacterium tuberculosis. Int. J. Antimicrob. Agents 28:543-544. 
www.intechopen.com
In Search of Eldorado: Current Trends  
and Strategies in the Development of Novel Anti-Tubercular Drugs 
 
125 
Alahari, A., X. Trivelli, Y. Guerardel, L. G. Dover, G. S. Besra, J. C. Sacchettini, R. C. 
Reynolds, G. D. Coxon, and L. Kremer. 2007. Thiacetazone, an antitubercular drug 
that inhibits cyclopropanation of cell wall mycolic acids in mycobacteria. PLoS. 
One. 2:e1343. 
am Ende, C. W., S. E. Knudson, N. Liu, J. Childs, T. J. Sullivan, M. Boyne, H. Xu, Y. Gegina, 
D. L. Knudson, F. Johnson, C. A. Peloquin, R. A. Slayden, and P. J. Tonge. 2008. 
Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether 
InhA inhibitors. Bioorg. Med. Chem. Lett. 18:3029-3033. 
Amaral, L., M. J. Boeree, S. H. Gillespie, Z. F. Udwadia, and S. D. van. 2010. Thioridazine 
cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global 
trials is now! Int. J. Antimicrob. Agents 35:524-526. 
Amaral, L. and J. E. Kristiansen. 2000. Phenothiazines: an alternative to conventional 
therapy for the initial management of suspected multidrug resistant tuberculosis. A 
call for studies. Int. J. Antimicrob. Agents 14:173-176. 
Amaral, L., J. E. Kristiansen, L. S. Abebe, and W. Millett. 1996. Inhibition of the respiration of 
multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: 
potential use for initial therapy of freshly diagnosed tuberculosis. J. Antimicrob. 
Chemother. 38:1049-1053. 
Amaral, L., A. Martins, J. Molnar, J. E. Kristiansen, M. Martins, M. Viveiros, L. Rodrigues, G. 
Spengler, I. Couto, J. Ramos, S. Dastidar, S. Fanning, M. McCusker, and J. M. Pages. 
2010. Phenothiazines, bacterial efflux pumps and targeting the macrophage for 
enhanced killing of intracellular XDRTB. In Vivo 24:409-424. 
Amaral, L., M. Martins, and M. Viveiros. 2007. Enhanced killing of intracellular multidrug-
resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux 
pumps. J. Antimicrob. Chemother. 59:1237-1246. 
Amaral, L., M. Martins, and M. Viveiros. 2007. Phenothiazines as anti-multi-drug resistant 
tubercular agents. Infect. Disord. Drug Targets. 7:257-265. 
Amaral, L., M. Martins, M. Viveiros, J. Molnar, and J. E. Kristiansen. 2008. Promising 
therapy of XDR-TB/MDR-TB with thioridazine an inhibitor of bacterial efflux 
pumps. Curr. Drug Targets. 9:816-819. 
Amaral, L. and J. Molnar. 2010. Therapy Of XDR TB with thioridazine a drug beyond patent 
protection but eligible for patent "as new use". Recent Pat Antiinfect. Drug Discov. 
5:109-114. 
Amaral, L., M. Viveiros, and J. Molnar. 2004. Antimicrobial activity of phenothiazines. In 
Vivo 18:725-731. 
Ananthan, S., E. R. Faaleolea, R. C. Goldman, J. V. Hobrath, C. D. Kwong, B. E. Laughon, J. 
A. Maddry, A. Mehta, L. Rasmussen, R. C. Reynolds, J. A. Secrist, III, N. Shindo, D. 
N. Showe, M. I. Sosa, W. J. Suling, and E. L. White. 2009. High-throughput 
screening for inhibitors of Mycobacterium tuberculosis H37Rv. Tuberculosis. (Edinb. ) 
89:334-353. 
Arcus, V. L., J. S. Lott, J. M. Johnston, and E. N. Baker. 2006. The potential impact of 
structural genomics on tuberculosis drug discovery. Drug Discov. Today 11:28-34. 
Banerjee, A., E. Dubnau, A. Quemard, V. Balasubramanian, K. S. Um, T. Wilson, D. Collins, 
L. G. de, and W. R. Jacobs, Jr. 1994. inhA, a gene encoding a target for isoniazid and 
ethionamide in Mycobacterium tuberculosis. Science 263:227-230. 
www.intechopen.com
 
Understanding Tuberculosis – New Approaches to Fighting Against Drug Resistance 
 
126 
Bardarov, S., Bardarov Jr S Jr, J. M. Pavelka, Jr., V. Sambandamurthy, M. Larsen, J. 
Tufariello, J. Chan, G. Hatfull, and J. W. Jacobs, Jr. 2002. Specialized transduction: 
an efficient method for generating marked and unmarked targeted gene 
disruptions in Mycobacterium tuberculosis, M. bovis BCG and M. smegmatis. 
Microbiology 148:3007-3017. 
Bashiri, G., C. J. Squire, N. J. Moreland, and E. N. Baker. 2008. Crystal structures of F420-
dependent glucose-6-phosphate dehydrogenase FGD1 involved in the activation of 
the anti-tuberculosis drug candidate PA-824 reveal the basis of coenzyme and 
substrate binding. J. Biol. Chem. 283:17531-17541. 
Bate, A. B., J. H. Kalin, E. M. Fooksman, E. L. Amorose, C. M. Price, H. M. Williams, M. J. 
Rodig, M. O. Mitchell, S. H. Cho, Y. Wang, and S. G. Franzblau. 2007. Synthesis and 
antitubercular activity of quaternized promazine and promethazine derivatives. 
Bioorg. Med. Chem. Lett. 17:1346-1348. 
Baughn, A. D., J. Deng, C. Vilcheze, A. Riestra, J. T. Welch, W. R. Jacobs, Jr., and O. 
Zimhony. 2010. Mutually exclusive genotypes for pyrazinamide and 5-
chloropyrazinamide resistance reveal a potential resistance-proofing strategy. 
Antimicrob. Agents Chemother. 54:5323-5328. 
Baulard, A. R., J. C. Betts, J. Engohang-Ndong, S. Quan, R. A. McAdam, P. J. Brennan, C. 
Locht, and G. S. Besra. 2000. Activation of the pro-drug ethionamide is regulated in 
mycobacteria. J. Biol. Chem. 275:28326-28331. 
Belanger, A. E., G. S. Besra, M. E. Ford, K. Mikusova, J. T. Belisle, P. J. Brennan, and J. M. 
Inamine. 1996. The embAB genes of Mycobacterium avium encode an arabinosyl 
transferase involved in cell wall arabinan biosynthesis that is the target for the 
antimycobacterial drug ethambutol. Proc. Natl. Acad. Sci. U. S. A 93:11919-11924. 
Bhowruth, V., A. K. Brown, and G. S. Besra. 2008. Synthesis and biological evaluation of 
NAS-21 and NAS-91 analogues as potential inhibitors of the mycobacterial FAS-II 
dehydratase enzyme Rv0636. Microbiology 154:1866-1875. 
Bhowruth, V., A. K. Brown, R. C. Reynolds, G. D. Coxon, S. P. Mackay, D. E. Minnikin, and 
G. S. Besra. 2006. Symmetrical and unsymmetrical analogues of isoxyl; active 
agents against Mycobacterium tuberculosis. Bioorg. Med. Chem. Lett. 16:4743-4747. 
Bianco, M. V., F. C. Blanco, B. Imperiale, M. A. Forrellad, R. V. Rocha, L. I. Klepp, A. A. 
Cataldi, N. Morcillo, and F. Bigi. 2011. Role of P27 -P55 operon from Mycobacterium 
tuberculosis in the resistance to toxic compounds. BMC. Infect. Dis. 11:195. 
Bloch, K. 1975. Fatty acid synthases from Mycobacterium phlei. Methods Enzymol. 35:84-90. 
Bloch, K. 1977. Control mechanisms for fatty acid synthesis in Mycobacterium smegmatis. 
Adv. Enzymol. Relat Areas Mol. Biol. 45:1-84. 
Boshoff, H. I., V. Mizrahi, and C. E. Barry, III. 2002. Effects of pyrazinamide on fatty acid 
synthesis by whole mycobacterial cells and purified fatty acid synthase I. J. 
Bacteriol. 184:2167-2172. 
Braibant, M., P. Gilot, and J. Content. 2000. The ATP binding cassette (ABC) transport 
systems of Mycobacterium tuberculosis. FEMS Microbiol. Rev. 24:449-467. 
Burguiere, A., P. G. Hitchen, L. G. Dover, A. Dell, and G. S. Besra. 2005. Altered expression 
profile of mycobacterial surface glycopeptidolipids following treatment with the 
antifungal azole inhibitors econazole and clotrimazole. Microbiology 151:2087-2095. 
Camacho, L. R., P. Constant, C. Raynaud, M. A. Laneelle, J. A. Triccas, B. Gicquel, M. Daffe, 
and C. Guilhot. 2001. Analysis of the phthiocerol dimycocerosate locus of 
www.intechopen.com
In Search of Eldorado: Current Trends  
and Strategies in the Development of Novel Anti-Tubercular Drugs 
 
127 
Mycobacterium tuberculosis. Evidence that this lipid is involved in the cell wall 
permeability barrier. J. Biol. Chem. 276:19845-19854. 
Chang Blanc, D. and P. Nunn. 2000. Incentives and Disincentives for new anti-tuberculosis 
drug development. Situational Analysis. World Health Organization, Geneva. 
Chim, N., J. E. Habel, J. M. Johnston, I. Krieger, L. Miallau, R. Sankaranarayanan, R. P. 
Morse, J. Bruning, S. Swanson, H. Kim, C. Y. Kim, H. Li, E. M. Bulloch, R. J. Payne, 
A. Manos-Turvey, L. W. Hung, E. N. Baker, J. S. Lott, M. N. James, T. C. 
Terwilliger, D. S. Eisenberg, J. C. Sacchettini, and C. W. Goulding. 2011. The TB 
structural genomics consortium: a decade of progress. Tuberculosis. (Edinb. ) 
91:155-172. 
Choi, K. P., T. B. Bair, Y. M. Bae, and L. Daniels. 2001. Use of transposon Tn5367 
mutagenesis and a nitroimidazopyran-based selection system to demonstrate a 
requirement for fbiA and fbiB in coenzyme F(420) biosynthesis by Mycobacterium 
bovis BCG. J. Bacteriol. 183:7058-7066. 
Choi, K. P., N. Kendrick, and L. Daniels. 2002. Demonstration that fbiC is required by 
Mycobacterium bovis BCG for coenzyme F(420) and FO biosynthesis. J. Bacteriol. 
184:2420-2428. 
Choudhuri, B. S., S. Sen, and P. Chakrabarti. 1999. Isoniazid accumulation in obacterium 
tuberculosis is modulated by proton motive force-driven and ATP-dependent 
extrusion systems. Biochem. Biophys. Res. Commun. 256:682-684. 
Cole, S. T., R. Brosch, J. Parkhill, T. Garnier, C. Churcher, D. Harris, S. V. Gordon, K. 
Eiglmeier, S. Gas, C. E. Barry, III, F. Tekaia, K. Badcock, D. Basham, D. Brown, T. 
Chillingworth, R. Connor, R. Davies, K. Devlin, T. Feltwell, S. Gentles, N. Hamlin, 
S. Holroyd, T. Hornsby, K. Jagels, A. Krogh, J. McLean, S. Moule, L. Murphy, K. 
Oliver, J. Osborne, M. A. Quail, M. A. Rajandream, J. Rogers, S. Rutter, K. Seeger, J. 
Skelton, R. Squares, S. Squares, J. E. Sulston, K. Taylor, S. Whitehead, and B. G. 
Barrell. 1998. Deciphering the biology of Mycobacterium tuberculosis from the 
complete genome sequence. Nature 393:537-544. 
Cole, S. T., K. Eiglmeier, J. Parkhill, K. D. James, N. R. Thomson, P. R. Wheeler, N. Honore, 
T. Garnier, C. Churcher, D. Harris, K. Mungall, D. Basham, D. Brown, T. 
Chillingworth, R. Connor, R. M. Davies, K. Devlin, S. Duthoy, T. Feltwell, A. Fraser, 
N. Hamlin, S. Holroyd, T. Hornsby, K. Jagels, C. Lacroix, J. Maclean, S. Moule, L. 
Murphy, K. Oliver, M. A. Quail, M. A. Rajandream, K. M. Rutherford, S. Rutter, K. 
Seeger, S. Simon, M. Simmonds, J. Skelton, R. Squares, S. Squares, K. Stevens, K. 
Taylor, S. Whitehead, J. R. Woodward, and B. G. Barrell. 2001. Massive gene decay 
in the leprosy bacillus. Nature 409:1007-1011. 
Collins, H. L. and S. H. Kaufmann. 2001. The many faces of host responses to tuberculosis. 
Immunology 103:1-9. 
Converse, S. E., J. D. Mougous, M. D. Leavell, J. A. Leary, C. R. Bertozzi, and J. S. Cox. 2003. 
MmpL8 is required for sulfolipid-1 biosynthesis and Mycobacterium tuberculosis 
virulence. Proc. Natl. Acad. Sci. U. S. A 100:6121-6126. 
Crowle, A. J., G. S. Douvas, and M. H. May. 1992. Chlorpromazine: a drug potentially useful 
for treating mycobacterial infections. Chemotherapy 38:410-419. 
Cynamon, M. H., R. J. Speirs, and J. T. Welch. 1998. In vitro antimycobacterial activity of 5-
chloropyrazinamide. Antimicrob. Agents Chemother. 42:462-463. 
www.intechopen.com
 
Understanding Tuberculosis – New Approaches to Fighting Against Drug Resistance 
 
128 
De Rossi, E., J. A. Ainsa, and G. Riccardi. 2006. Role of mycobacterial efflux transporters in 
drug resistance: an unresolved question. FEMS Microbiol. Rev. 30:36-52. 
De Rossi, E., P. Arrigo, M. Bellinzoni, P. A. Silva, C. Martin, J. A. Ainsa, P. Guglierame, and 
G. Riccardi. 2002. The multidrug transporters belonging to major facilitator 
superfamily in Mycobacterium tuberculosis. Mol. Med. 8:714-724. 
De Rossi, E., P. Arrigo, M. Bellinzoni, P. A. Silva, C. Martin, J. A. Ainsa, P. Guglierame, and 
G. Riccardi. 2002. The multidrug transporters belonging to major facilitator 
superfamily in Mycobacterium tuberculosis. Mol. Med. 8:714-724. 
De Rossi, E., M. Branzoni, R. Cantoni, A. Milano, G. Riccardi, and O. Ciferri. 1998. mmr, a 
Mycobacterium tuberculosis gene conferring resistance to small cationic dyes and 
inhibitors. J. Bacteriol. 180:6068-6071. 
Debarber, A. E., K. Mdluli, M. Bosman, L. G. Bekker, and C. E. Barry, III. 2000. Ethionamide 
activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. Proc. 
Natl. Acad. Sci. U. S. A 97:9677-9682. 
Denny, W. A. and B. D. Palmer. 2010. The nitroimidazooxazines (PA-824 and analogs): 
structure-activity relationship and mechanistic studies. Future. Med. Chem. 2:1295-
1304. 
Deshayes, C., H. Bach, D. Euphrasie, R. Attarian, M. Coureuil, W. Sougakoff, F. Laval, Y. 
Av-Gay, M. Daffe, G. Etienne, and J. M. Reyrat. 2010. MmpS4 promotes 
glycopeptidolipids biosynthesis and export in Mycobacterium smegmatis. Mol. 
Microbiol. 78:989-1003. 
Diacon, A. H., A. Pym, M. Grobusch, R. Patientia, R. Rustomjee, L. Page-Shipp, C. Pistorius, 
R. Krause, M. Bogoshi, G. Churchyard, A. Venter, J. Allen, J. C. Palomino, M. T. De, 
R. P. van Heeswijk, N. Lounis, P. Meyvisch, J. Verbeeck, W. Parys, B. K. de, K. 
Andries, and D. F. Mc Neeley. 2009. The diarylquinoline TMC207 for multidrug-
resistant tuberculosis. N. Engl. J. Med. 360:2397-2405. 
Domenech, P., M. B. Reed, and C. E. Barry, III. 2005. Contribution of the Mycobacterium 
tuberculosis MmpL protein family to virulence and drug resistance. Infect. Immun. 
73:3492-3501. 
Dover, L. G., A. Alahari, P. Gratraud, J. M. Gomes, V. Bhowruth, R. C. Reynolds, G. S. Besra, 
and L. Kremer. 2007. EthA, a common activator of thiocarbamide-containing drugs 
acting on different mycobacterial targets. Antimicrob. Agents Chemother. 51:1055-
1063. 
Druilhe, P., P. Hagan, and G. A. Rook. 2002. The importance of models of infection in the 
study of disease resistance. Trends Microbiol. 10:S38-S46. 
Dutta, N. K., K. Mazumdar, S. G. Dastidar, P. C. Karakousis, and L. Amaral. 2011. New 
patentable use of an old neuroleptic compound thioridazine to combat 
tuberculosis: a gene regulation perspective. Recent Pat Antiinfect. Drug Discov. 
6:128-138. 
Flynn, J. L. 2006. Lessons from experimental Mycobacterium tuberculosis infections. Microbes. 
Infect. 8:1179-1188. 
Flynn, J. L., S. V. Capuano, D. Croix, S. Pawar, A. Myers, A. Zinovik, and E. Klein. 2003. 
Non-human primates: a model for tuberculosis research. Tuberculosis. (Edinb. ) 
83:116-118. 
www.intechopen.com
In Search of Eldorado: Current Trends  
and Strategies in the Development of Novel Anti-Tubercular Drugs 
 
129 
Frenois, F., J. Engohang-Ndong, C. Locht, A. R. Baulard, and V. Villeret. 2004. Structure of 
EthR in a ligand bound conformation reveals therapeutic perspectives against 
tuberculosis. Mol. Cell 16:301-307. 
Freundlich, J. S., F. Wang, C. Vilcheze, G. Gulten, R. Langley, G. A. Schiehser, D. P. Jacobus, 
W. R. Jacobs, Jr., and J. C. Sacchettini. 2009. Triclosan derivatives: towards potent 
inhibitors of drug-sensitive and drug-resistant Mycobacterium tuberculosis. 
ChemMedChem. 4:241-248. 
Gardner, C. A., T. Acharya, and A. Pablos-Mendez. 2005. The global alliance for tuberculosis 
drug development--accomplishments and future directions. Clin. Chest Med. 
26:341-7, vii. 
Ginsberg, A. M. 2010. Drugs in development for tuberculosis. Drugs 70:2201-2214. 
Ginsberg, A. M., M. W. Laurenzi, D. J. Rouse, K. D. Whitney, and M. K. Spigelman. 2009. 
Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects. 
Antimicrob. Agents Chemother. 53:3720-3725. 
Goulding, C. W., M. Apostol, D. H. Anderson, H. S. Gill, C. V. Smith, M. R. Kuo, J. K. Yang, 
G. S. Waldo, S. W. Suh, R. Chauhan, A. Kale, N. Bachhawat, S. C. Mande, J. M. 
Johnston, J. S. Lott, E. N. Baker, V. L. Arcus, D. Leys, K. J. McLean, A. W. Munro, J. 
Berendzen, V. Sharma, M. S. Park, D. Eisenberg, J. Sacchettini, T. Alber, B. Rupp, 
W. Jacobs, Jr., and T. C. Terwilliger. 2002. The TB structural genomics consortium: 
providing a structural foundation for drug discovery. Curr. Drug Targets. Infect. 
Disord. 2:121-141. 
Guilhot, C., I. Otal, R. Van, I, C. Martin, and B. Gicquel. 1994. Efficient transposition in 
mycobacteria: construction of Mycobacterium smegmatis insertional mutant libraries. 
J. Bacteriol. 176:535-539. 
Gupta, A. K., V. M. Katoch, D. S. Chauhan, R. Sharma, M. Singh, K. Venkatesan, and V. D. 
Sharma. 2010. Microarray analysis of efflux pump genes in multidrug-resistant 
Mycobacterium tuberculosis during stress induced by common anti-tuberculous 
drugs. Microb. Drug Resist. 16:21-28. 
Haagsma, A. C., R. bdillahi-Ibrahim, M. J. Wagner, K. Krab, K. Vergauwen, J. Guillemont, K. 
Andries, H. Lill, A. Koul, and D. Bald. 2009. Selectivity of TMC207 towards 
mycobacterial ATP synthase compared with that towards the eukaryotic 
homologue. Antimicrob. Agents Chemother. 53:1290-1292. 
Heym, B., P. M. Alzari, N. Honore, and S. T. Cole. 1995. Missense mutations in the catalase-
peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium 
tuberculosis. Mol. Microbiol. 15:235-245. 
Holsclaw, C. M., K. M. Sogi, S. A. Gilmore, M. W. Schelle, M. D. Leavell, C. R. Bertozzi, and 
J. A. Leary. 2008. Structural characterization of a novel sulfated menaquinone 
produced by stf3 from Mycobacterium tuberculosis. ACS Chem. Biol. 3:619-624. 
Huang, Q., P. J. Tonge, R. A. Slayden, T. Kirikae, and I. Ojima. 2007. FtsZ: a novel target for 
tuberculosis drug discovery. Curr. Top. Med. Chem. 7:527-543. 
Ibrahim, M., K. Andries, N. Lounis, A. Chauffour, C. Truffot-Pernot, V. Jarlier, and N. 
Veziris. 2007. Synergistic activity of R207910 combined with pyrazinamide against 
murine tuberculosis. Antimicrob. Agents Chemother. 51:1011-1015. 
Ibrahim, M., C. Truffot-Pernot, K. Andries, V. Jarlier, and N. Veziris. 2009. Sterilizing 
activity of R207910 (TMC207)-containing regimens in the murine model of 
tuberculosis. Am. J. Respir. Crit Care Med. 180:553-557. 
www.intechopen.com
 
Understanding Tuberculosis – New Approaches to Fighting Against Drug Resistance 
 
130 
Jackson, M., C. L. Reinaldo, B. Gicquel, and C. Guilhot. 2001. Gene Replacement and 
Transposon Delivery Using the Negative Selection Marker sacB. Methods Mol. 
Med. 54:59-75. 
Jain, M. and J. S. Cox. 2005. Interaction between polyketide synthase and transporter 
suggests coupled synthesis and export of virulence lipid in M. tuberculosis. PLoS. 
Pathog. 1:e2. 
Jia, L., L. Coward, G. S. Gorman, P. E. Noker, and J. E. Tomaszewski. 2005. 
Pharmacoproteomic effects of isoniazid, ethambutol, and N-geranyl-N'-(2-
adamantyl)ethane-1,2-diamine (SQ109) on Mycobacterium tuberculosis H37Rv. J. 
Pharmacol. Exp. Ther. 315:905-911. 
Jiang, X., W. Zhang, Y. Zhang, F. Gao, C. Lu, X. Zhang, and H. Wang. 2008. Assessment of 
efflux pump gene expression in a clinical isolate Mycobacterium tuberculosis by real-
time reverse transcription PCR. Microb. Drug Resist. 14:7-11. 
Jureen, P., J. Werngren, J. C. Toro, and S. Hoffner. 2008. Pyrazinamide resistance and pncA 
gene mutations in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 
52:1852-1854. 
Kaufmann, S. H. 2006. Tuberculosis: back on the immunologists' agenda. Immunity. 24:351-
357. 
Kaufmann, S. H. and J. Hess. 2000. Immune response against Mycobacterium tuberculosis: 
implications for vaccine development. J. Biotechnol. 83:13-17. 
Khoo, K. H., E. Douglas, P. Azadi, J. M. Inamine, G. S. Besra, K. Mikusova, P. J. Brennan, and 
D. Chatterjee. 1996. Truncated structural variants of lipoarabinomannan in 
ethambutol drug-resistant strains of Mycobacterium smegmatis. Inhibition of 
arabinan biosynthesis by ethambutol. J. Biol. Chem. 271:28682-28690. 
Kordulakova, J., Y. L. Janin, A. Liav, N. Barilone, V. T. Dos, J. Rauzier, P. J. Brennan, B. 
Gicquel, and M. Jackson. 2007. Isoxyl activation is required for bacteriostatic 
activity against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 51:3824-
3829. 
Koul, A., N. Dendouga, K. Vergauwen, B. Molenberghs, L. Vranckx, R. Willebrords, Z. 
Ristic, H. Lill, I. Dorange, J. Guillemont, D. Bald, and K. Andries. 2007. 
Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat. Chem. Biol. 
3:323-324. 
Koul, A., L. Vranckx, N. Dendouga, W. Balemans, d. W. Van, I, K. Vergauwen, H. W. 
Gohlmann, R. Willebrords, A. Poncelet, J. Guillemont, D. Bald, and K. Andries. 
2008. Diarylquinolines are bactericidal for dormant mycobacteria as a result of 
disturbed ATP homeostasis. J. Biol. Chem. 283:25273-25280. 
Kristiansen, J. E. 1989. Dyes, antipsychotic drugs, and antimicrobial activity. Fragments of a 
development, with special reference to the influence of Paul Ehrlich. Dan. Med. 
Bull. 36:178-185. 
Kristiansen, J. E. and L. Amaral. 1997. The potential management of resistant infections with 
non-antibiotics. J. Antimicrob. Chemother. 40:319-327. 
Kumar, K., D. Awasthi, W. T. Berger, P. J. Tonge, R. A. Slayden, and I. Ojima. 2010. 
Discovery of anti-TB agents that target the cell-division protein FtsZ. Future. Med. 
Chem. 2:1305-1323. 
www.intechopen.com
In Search of Eldorado: Current Trends  
and Strategies in the Development of Novel Anti-Tubercular Drugs 
 
131 
Kurth, D. G., G. M. Gago, l. de, I, L. B. Bazet, T. W. Lin, H. R. Morbidoni, S. C. Tsai, and H. 
Gramajo. 2009. ACCase 6 is the essential acetyl-CoA carboxylase involved in fatty 
acid and mycolic acid biosynthesis in mycobacteria. Microbiology 155:2664-2675. 
Lamichhane, G., M. Zignol, N. J. Blades, D. E. Geiman, A. Dougherty, J. Grosset, K. W. 
Broman, and W. R. Bishai. 2003. A postgenomic method for predicting essential 
genes at subsaturation levels of mutagenesis: application to Mycobacterium 
tuberculosis. Proc. Natl. Acad. Sci. U. S. A 100:7213-7218. 
Laughon, B. E. 2007. New tuberculosis drugs in development. Curr. Top. Med. Chem. 7:463-
473. 
Lenaerts, A. J., V. Gruppo, K. S. Marietta, C. M. Johnson, D. K. Driscoll, N. M. Tompkins, J. 
D. Rose, R. C. Reynolds, and I. M. Orme. 2005. Preclinical testing of the 
nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series 
of in vitro and in vivo models. Antimicrob. Agents Chemother. 49:2294-2301. 
Li, X. Z., L. Zhang, and H. Nikaido. 2004. Efflux pump-mediated intrinsic drug resistance in 
Mycobacterium smegmatis. Antimicrob. Agents Chemother. 48:2415-2423. 
Lin, T. W., M. M. Melgar, D. Kurth, S. J. Swamidass, J. Purdon, T. Tseng, G. Gago, P. Baldi, 
H. Gramajo, and S. C. Tsai. 2006. Structure-based inhibitor design of AccD5, an 
essential acyl-CoA carboxylase carboxyltransferase domain of Mycobacterium 
tuberculosis. Proc. Natl. Acad. Sci. U. S. A 103:3072-3077. 
Liu, J., C. E. Barry, III, G. S. Besra, and H. Nikaido. 1996. Mycolic acid structure determines 
the fluidity of the mycobacterial cell wall. J. Biol. Chem. 271:29545-29551. 
Liu, J., H. E. Takiff, and H. Nikaido. 1996. Active efflux of fluoroquinolones in Mycobacterium 
smegmatis mediated by LfrA, a multidrug efflux pump. J. Bacteriol. 178:3791-3795. 
Maddry, J. A., S. Ananthan, R. C. Goldman, J. V. Hobrath, C. D. Kwong, C. Maddox, L. 
Rasmussen, R. C. Reynolds, J. A. Secrist, III, M. I. Sosa, E. L. White, and W. Zhang. 
2009. Antituberculosis activity of the molecular libraries screening center network 
library. Tuberculosis. (Edinb. ) 89:354-363. 
Makarov, V., G. Manina, K. Mikusova, U. Mollmann, O. Ryabova, B. Saint-Joanis, N. Dhar, 
M. R. Pasca, S. Buroni, A. P. Lucarelli, A. Milano, R. E. De, M. Belanova, A. 
Bobovska, P. Dianiskova, J. Kordulakova, C. Sala, E. Fullam, P. Schneider, J. D. 
McKinney, P. Brodin, T. Christophe, S. Waddell, P. Butcher, J. Albrethsen, I. 
Rosenkrands, R. Brosch, V. Nandi, S. Bharath, S. Gaonkar, R. K. Shandil, V. 
Balasubramanian, T. Balganesh, S. Tyagi, J. Grosset, G. Riccardi, and S. T. Cole. 
2009. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan 
synthesis. Science 324:801-804. 
Manina, G., M. R. Pasca, S. Buroni, R. E. De, and G. Riccardi. 2010. Decaprenylphosphoryl-
beta-D-ribose 2'-epimerase from Mycobacterium tuberculosis is a magic drug target. 
Curr. Med. Chem. 17:3099-3108. 
Manjunatha, U. H., H. Boshoff, C. S. Dowd, L. Zhang, T. J. Albert, J. E. Norton, L. Daniels, T. 
Dick, S. S. Pang, and C. E. Barry, III. 2006. Identification of a nitroimidazo-oxazine-
specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc. 
Natl. Acad. Sci. U. S. A 103:431-436. 
Martins, M., Z. Schelz, A. Martins, J. Molnar, G. Hajos, Z. Riedl, M. Viveiros, I. Yalcin, E. ki-
Sener, and L. Amaral. 2007. In vitro and ex vivo activity of thioridazine derivatives 
against Mycobacterium tuberculosis. Int. J. Antimicrob. Agents 29:338-340. 
www.intechopen.com
 
Understanding Tuberculosis – New Approaches to Fighting Against Drug Resistance 
 
132 
Martins, M., M. Viveiros, and L. Amaral. 2008. Inhibitors of Ca2+ and K+ transport enhance 
intracellular killing of M. tuberculosis by non-killing macrophages. In Vivo 22:69-
75. 
Martins, M., M. Viveiros, I. Couto, and L. Amaral. 2009. Targeting human macrophages for 
enhanced killing of intracellular XDR-TB and MDR-TB. Int. J. Tuberc. Lung Dis. 
13:569-573. 
Martins, M., M. Viveiros, J. E. Kristiansen, J. Molnar, and L. Amaral. 2007. The curative 
activity of thioridazine on mice infected with Mycobacterium tuberculosis. In Vivo 
21:771-775. 
Matsumoto, M., H. Hashizume, T. Tomishige, M. Kawasaki, H. Tsubouchi, H. Sasaki, Y. 
Shimokawa, and M. Komatsu. 2006. OPC-67683, a nitro-dihydro-imidazooxazole 
derivative with promising action against tuberculosis in vitro and in mice. PLoS. 
Med. 3:e466. 
Matteelli, A., A. C. Carvalho, K. E. Dooley, and A. Kritski. 2010. TMC207: the first 
compound of a new class of potent anti-tuberculosis drugs. Future. Microbiol. 
5:849-858. 
McLean, K. J., P. Carroll, D. G. Lewis, A. J. Dunford, H. E. Seward, R. Neeli, M. R. 
Cheesman, L. Marsollier, P. Douglas, W. E. Smith, I. Rosenkrands, S. T. Cole, D. 
Leys, T. Parish, and A. W. Munro. 2008. Characterization of active site structure in 
CYP121. A cytochrome P450 essential for viability of Mycobacterium tuberculosis 
H37Rv. J. Biol. Chem. 283:33406-33416. 
Miesel, L., T. R. Weisbrod, J. A. Marcinkeviciene, R. Bittman, and W. R. Jacobs, Jr. 1998. 
NADH dehydrogenase defects confer isoniazid resistance and conditional lethality 
in Mycobacterium smegmatis. J. Bacteriol. 180:2459-2467. 
Milano, A., M. R. Pasca, R. Provvedi, A. P. Lucarelli, G. Manina, A. L. Ribeiro, R. 
Manganelli, and G. Riccardi. 2009. Azole resistance in Mycobacterium tuberculosis is 
mediated by the MmpS5-MmpL5 efflux system. Tuberculosis. (Edinb. ) 89:84-90. 
Mitchison, D. A. and K. C. Chang. 2009. Experimental models of tuberculosis: can we trust 
the mouse? Am. J. Respir. Crit Care Med. 180:201-202. 
Morlock, G. P., B. Metchock, D. Sikes, J. T. Crawford, and R. C. Cooksey. 2003. ethA, inhA, 
and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. 
Antimicrob. Agents Chemother. 47:3799-3805. 
Munoz-Elias, E. J. and J. D. McKinney. 2005. Mycobacterium tuberculosis isocitrate lyases 1 
and 2 are jointly required for in vivo growth and virulence. Nat. Med. 11:638-644. 
Nikaido, H. and V. Jarlier. 1991. Permeability of the mycobacterial cell wall. Res. Microbiol. 
142:437-443. 
Nishida, C. R. and P. R. Ortiz de Montellano. 2011. Bioactivation of antituberculosis 
thioamide and thiourea prodrugs by bacterial and mammalian flavin 
monooxygenases. Chem. Biol. Interact. 192:21-25. 
Nuermberger, E., I. Rosenthal, S. Tyagi, K. N. Williams, D. Almeida, C. A. Peloquin, W. R. 
Bishai, and J. H. Grosset. 2006. Combination chemotherapy with the 
nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. 
Antimicrob. Agents Chemother. 50:2621-2625. 
O'Brien, R. J. and P. P. Nunn. 2001. The need for new drugs against tuberculosis. Obstacles, 
opportunities, and next steps. Am. J. Respir. Crit Care Med. 163:1055-1058. 
www.intechopen.com
In Search of Eldorado: Current Trends  
and Strategies in the Development of Novel Anti-Tubercular Drugs 
 
133 
Ojha, A. K., A. D. Baughn, D. Sambandan, T. Hsu, X. Trivelli, Y. Guerardel, A. Alahari, L. 
Kremer, W. R. Jacobs, Jr., and G. F. Hatfull. 2008. Growth of Mycobacterium 
tuberculosis biofilms containing free mycolic acids and harbouring drug-tolerant 
bacteria. Mol. Microbiol. 69:164-174. 
Ordway, D., M. Viveiros, C. Leandro, R. Bettencourt, J. Almeida, M. Martins, J. E. 
Kristiansen, J. Molnar, and L. Amaral. 2003. Clinical concentrations of thioridazine 
kill intracellular multidrug-resistant Mycobacterium tuberculosis. Antimicrob. Agents 
Chemother. 47:917-922. 
Orme, I. 2001. Search for new drugs for treatment of tuberculosis. Antimicrob. Agents 
Chemother. 45:1943-1946. 
Pablos-Mendez, A. 2000. Working alliance for TB drug development, Cape Town, South 
Africa, February 8th, 2000. Int. J. Tuberc. Lung Dis. 4:489-490. 
Pasca, M. R., P. Guglierame, F. Arcesi, M. Bellinzoni, R. E. De, and G. Riccardi. 2004. 
Rv2686c-Rv2687c-Rv2688c, an ABC fluoroquinolone efflux pump in Mycobacterium 
tuberculosis. Antimicrob. Agents Chemother. 48:3175-3178. 
Pasca, M. R., P. Guglierame, R. E. De, F. Zara, and G. Riccardi. 2005. mmpL7 gene of 
Mycobacterium tuberculosis is responsible for isoniazid efflux in Mycobacterium 
smegmatis. Antimicrob. Agents Chemother. 49:4775-4777. 
Perrin, F. M., N. Woodward, P. P. Phillips, T. D. McHugh, A. J. Nunn, M. C. Lipman, and S. 
H. Gillespie. 2010. Radiological cavitation, sputum mycobacterial load and 
treatment response in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 14:1596-
1602. 
Protopopova, M., C. Hanrahan, B. Nikonenko, R. Samala, P. Chen, J. Gearhart, L. Einck, and 
C. A. Nacy. 2005. Identification of a new antitubercular drug candidate, SQ109, 
from a combinatorial library of 1,2-ethylenediamines. J. Antimicrob. Chemother. 
56:968-974. 
Ramon-Garcia, S., C. Martin, C. J. Thompson, and J. A. Ainsa. 2009. Role of the 
Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative 
stress responses, and growth. Antimicrob. Agents Chemother. 53:3675-3682. 
Raynaud, C., M. A. Laneelle, R. H. Senaratne, P. Draper, G. Laneelle, and M. Daffe. 1999. 
Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of 
uptake in addition to lack of pyrazinamidase activity. Microbiology 145 ( Pt 
6):1359-1367. 
Rengarajan, J., B. R. Bloom, and E. J. Rubin. 2005. Genome-wide requirements for 
Mycobacterium tuberculosis adaptation and survival in macrophages. Proc. Natl. 
Acad. Sci. U. S. A 102:8327-8332. 
Russell, D. G., P. J. Cardona, M. J. Kim, S. Allain, and F. Altare. 2009. Foamy macrophages 
and the progression of the human tuberculosis granuloma. Nat. Immunol. 10:943-
948. 
Saliu, O. Y., C. Crismale, S. K. Schwander, and R. S. Wallis. 2007. Bactericidal activity of 
OPC-67683 against drug-tolerant Mycobacterium tuberculosis. J. Antimicrob. 
Chemother. 60:994-998. 
Sander, P., R. E. De, B. Boddinghaus, R. Cantoni, M. Branzoni, E. C. Bottger, H. Takiff, R. 
Rodriquez, G. Lopez, and G. Riccardi. 2000. Contribution of the multidrug efflux 
pump LfrA to innate mycobacterial drug resistance. FEMS Microbiol. Lett. 193:19-
23. 
www.intechopen.com
 
Understanding Tuberculosis – New Approaches to Fighting Against Drug Resistance 
 
134 
Sasaki, H., Y. Haraguchi, M. Itotani, H. Kuroda, H. Hashizume, T. Tomishige, M. Kawasaki, 
M. Matsumoto, M. Komatsu, and H. Tsubouchi. 2006. Synthesis and 
antituberculosis activity of a novel series of optically active 6-nitro-2,3-
dihydroimidazo[2,1-b]oxazoles. J. Med. Chem. 49:7854-7860. 
Sassetti, C. M., D. H. Boyd, and E. J. Rubin. 2001. Comprehensive identification of 
conditionally essential genes in mycobacteria. Proc. Natl. Acad. Sci. U. S. A 
98:12712-12717. 
Sassetti, C. M., D. H. Boyd, and E. J. Rubin. 2003. Genes required for mycobacterial growth 
defined by high density mutagenesis. Mol. Microbiol. 48:77-84. 
Silva, P. E., F. Bigi, M. P. Santangelo, M. I. Romano, C. Martin, A. Cataldi, and J. A. Ainsa. 
2001. Characterization of P55, a multidrug efflux pump in Mycobacterium bovis and 
Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 45:800-804. 
Singh, R., U. Manjunatha, H. I. Boshoff, Y. H. Ha, P. Niyomrattanakit, R. Ledwidge, C. S. 
Dowd, I. Y. Lee, P. Kim, L. Zhang, S. Kang, T. H. Keller, J. Jiricek, and C. E. Barry, 
III. 2008. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO 
release. Science 322:1392-1395. 
Slayden, R. A. and J. T. Belisle. 2009. Morphological features and signature gene response 
elicited by inactivation of FtsI in Mycobacterium tuberculosis. J. Antimicrob. 
Chemother. 63:451-457. 
Spigelman, M. K. 2007. New tuberculosis therapeutics: a growing pipeline. J. Infect. Dis. 196 
Suppl 1:S28-S34. 
Stephan, J., C. Mailaender, G. Etienne, M. Daffe, and M. Niederweis. 2004. Multidrug 
resistance of a porin deletion mutant of Mycobacterium smegmatis. Antimicrob. 
Agents Chemother. 48:4163-4170. 
Stover, C. K., P. Warrener, D. R. VanDevanter, D. R. Sherman, T. M. Arain, M. H. 
Langhorne, S. W. Anderson, J. A. Towell, Y. Yuan, D. N. McMurray, B. N. 
Kreiswirth, C. E. Barry, and W. R. Baker. 2000. A small-molecule 
nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 
405:962-966. 
Sullivan, T. J., J. J. Truglio, M. E. Boyne, P. Novichenok, X. Zhang, C. F. Stratton, H. J. Li, T. 
Kaur, A. Amin, F. Johnson, R. A. Slayden, C. Kisker, and P. J. Tonge. 2006. High 
affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium 
tuberculosis. ACS Chem. Biol. 1:43-53. 
Takayama, K. and J. O. Kilburn. 1989. Inhibition of synthesis of arabinogalactan by 
ethambutol in Mycobacterium smegmatis. Antimicrob. Agents Chemother. 33:1493-
1499. 
Telenti, A., W. J. Philipp, S. Sreevatsan, C. Bernasconi, K. E. Stockbauer, B. Wieles, J. M. 
Musser, and W. R. Jacobs, Jr. 1997. The emb operon, a gene cluster of Mycobacterium 
tuberculosis involved in resistance to ethambutol. Nat. Med. 3:567-570. 
Tonge, P. J., C. Kisker, and R. A. Slayden. 2007. Development of modern InhA inhibitors to 
combat drug resistant strains of Mycobacterium tuberculosis. Curr. Top. Med. Chem. 
7:489-498. 
Tsolaki, A. G., A. E. Hirsh, K. Deriemer, J. A. Enciso, M. Z. Wong, M. Hannan, Goguet de la 
Salmoniere YO, K. Aman, M. Kato-Maeda, and P. M. Small. 2004. Functional and 
evolutionary genomics of Mycobacterium tuberculosis: insights from genomic 
deletions in 100 strains. Proc. Natl. Acad. Sci. U. S. A 101:4865-4870. 
www.intechopen.com
In Search of Eldorado: Current Trends  
and Strategies in the Development of Novel Anti-Tubercular Drugs 
 
135 
Ulrichs, T. and S. H. Kaufmann. 2002. Mycobacterial persistence and immunity. Front Biosci. 
7:d458-d469. 
van den Boogaard, J., G. S. Kibiki, E. R. Kisanga, M. J. Boeree, and R. E. Aarnoutse. 2009. 
New drugs against tuberculosis: problems, progress, and evaluation of agents in 
clinical development. Antimicrob. Agents Chemother. 53:849-862. 
Van Imbden J., L. T. van der, L. Amaral, R. Dekhuijzen, M. J. Boeree, and S. D. van. 2009. In 
vitro activity of thioridazine against mycobacteria. Int. J. Antimicrob. Agents 
34:190-191. 
van Soolingen. D., R. Hernandez-Pando, H. Orozco, D. Aguilar, C. Magis-Escurra, L. 
Amaral, I. J. van, and M. J. Boeree. 2010. The antipsychotic thioridazine shows 
promising therapeutic activity in a mouse model of multidrug-resistant 
tuberculosis. PLoS. One. 5. 
Vannelli, T. A., A. Dykman, and P. R. Ortiz de Montellano. 2002. The antituberculosis drug 
ethionamide is activated by a flavoprotein monooxygenase. J. Biol. Chem. 
277:12824-12829. 
Vilcheze, C., Y. Av-Gay, R. Attarian, Z. Liu, M. H. Hazbon, R. Colangeli, B. Chen, W. Liu, D. 
Alland, J. C. Sacchettini, and W. R. Jacobs, Jr. 2008. Mycothiol biosynthesis is 
essential for ethionamide susceptibility in Mycobacterium tuberculosis. Mol. 
Microbiol. 69:1316-1329. 
Vilcheze, C., Y. Av-Gay, S. W. Barnes, M. H. Larsen, J. R. Walker, R. J. Glynne, and W. R. 
Jacobs, Jr. 2011. Coresistance to isoniazid and ethionamide maps to mycothiol 
biosynthetic genes in Mycobacterium bovis. Antimicrob. Agents Chemother.  
Vilcheze, C. and W. R. Jacobs, Jr. 2007. The mechanism of isoniazid killing: clarity through 
the scope of genetics. Annu. Rev. Microbiol. 61:35-50. 
Vilcheze, C., T. R. Weisbrod, B. Chen, L. Kremer, M. H. Hazbon, F. Wang, D. Alland, J. C. 
Sacchettini, and W. R. Jacobs, Jr. 2005. Altered NADH/NAD+ ratio mediates 
coresistance to isoniazid and ethionamide in mycobacteria. Antimicrob. Agents 
Chemother. 49:708-720. 
Viveiros, M. and L. Amaral. 2001. Enhancement of antibiotic activity against poly-drug 
resistant Mycobacterium tuberculosis by phenothiazines. Int. J. Antimicrob. Agents 
17:225-228. 
Viveiros, M., C. Leandro, and L. Amaral. 2003. Mycobacterial efflux pumps and 
chemotherapeutic implications. Int. J. Antimicrob. Agents 22:274-278. 
Viveiros, M., M. Martins, I. Couto, J. E. Kristiansen, J. Molnar, and L. Amaral. 2005. The in 
vitro activity of phenothiazines against Mycobacterium avium: potential of 
thioridazine for therapy of the co-infected AIDS patient. In Vivo 19:733-736. 
Viveiros, M., M. Martins, I. Couto, L. Rodrigues, D. Machado, I. Portugal, and L. Amaral. 
2010. Molecular tools for rapid identification and novel effective therapy against 
MDRTB/XDRTB infections. Expert. Rev. Anti. Infect. Ther. 8:465-480. 
Wayne, L. G. 1994. Dormancy of Mycobacterium tuberculosis and latency of disease. Eur. J. 
Clin. Microbiol. Infect. Dis. 13:908-914. 
Wayne, L. G. and K. Y. Lin. 1982. Glyoxylate metabolism and adaptation of Mycobacterium 
tuberculosis to survival under anaerobic conditions. Infect. Immun. 37:1042-1049. 
Weber, W., R. Schoenmakers, B. Keller, M. Gitzinger, T. Grau, B. M. oud-El, P. Sander, and 
M. Fussenegger. 2008. A synthetic mammalian gene circuit reveals antituberculosis 
compounds. Proc. Natl. Acad. Sci. U. S. A 105:9994-9998. 
www.intechopen.com
 
Understanding Tuberculosis – New Approaches to Fighting Against Drug Resistance 
 
136 
Weinstein, E. A., T. Yano, L. S. Li, D. Avarbock, A. Avarbock, D. Helm, A. A. McColm, K. 
Duncan, J. T. Lonsdale, and H. Rubin. 2005. Inhibitors of type II 
NADH:menaquinone oxidoreductase represent a class of antitubercular drugs. 
Proc. Natl. Acad. Sci. U. S. A 102:4548-4553. 
Willand, N., B. Dirie, X. Carette, P. Bifani, A. Singhal, M. Desroses, F. Leroux, E. Willery, V. 
Mathys, R. prez-Poulain, G. Delcroix, F. Frenois, M. Aumercier, C. Locht, V. 
Villeret, B. Deprez, and A. R. Baulard. 2009. Synthetic EthR inhibitors boost 
antituberculous activity of ethionamide. Nat. Med. 15:537-544. 
Xu, X., C. Vilcheze, Y. Av-Gay, A. Gomez-Velasco, and W. R. Jacobs, Jr. 2011. Precise Null 
Deletion Mutations of the Mycothiol Synthesis Genes Reveal Their Role in 
Isoniazid and Ethionamide Resistance in Mycobacterium smegmatis. Antimicrob. 
Agents Chemother. 55:3133-3139. 
Yano, T., L. S. Li, E. Weinstein, J. S. Teh, and H. Rubin. 2006. Steady-state kinetics and 
inhibitory action of antitubercular phenothiazines on Mycobacterium tuberculosis 
type-II NADH-menaquinone oxidoreductase (NDH-2). J. Biol. Chem. 281:11456-
11463. 
Zhang, Y. 2004. Persistent and dormant tubercle bacilli and latent tuberculosis. Front Biosci. 
9:1136-1156. 
Zhang, Y., B. Heym, B. Allen, D. Young, and S. Cole. 1992. The catalase-peroxidase gene and 
isoniazid resistance of Mycobacterium tuberculosis. Nature 358:591-593. 
Zhang, Y. and D. Mitchison. 2003. The curious characteristics of pyrazinamide: a review. Int. 
J. Tuberc. Lung Dis. 7:6-21. 
Zhang, Y., A. Scorpio, H. Nikaido, and Z. Sun. 1999. Role of acid pH and deficient efflux of 
pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to 
pyrazinamide. J. Bacteriol. 181:2044-2049. 
Zimhony, O., J. S. Cox, J. T. Welch, C. Vilcheze, and W. R. Jacobs, Jr. 2000. Pyrazinamide 
inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium 
tuberculosis. Nat. Med. 6:1043-1047. 
www.intechopen.com
Understanding Tuberculosis - New Approaches to Fighting
Against Drug Resistance
Edited by Dr. Pere-Joan Cardona
ISBN 978-953-307-948-6
Hard cover, 376 pages
Publisher InTech
Published online 15, February, 2012
Published in print edition February, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
In 1957, a Streptomyces strain, the ME/83 (S.mediterranei), was isolated in the Lepetit Research Laboratories
from a soil sample collected at a pine arboretum near Saint Raphael, France. This drug was the base for the
chemotherapy with Streptomicine. The euphoria generated by the success of this regimen lead to the idea that
TB eradication would be possible by the year 2000. Thus, any further drug development against TB was
stopped. Unfortunately, the lack of an accurate administration of these drugs originated the irruption of the
drug resistance in Mycobacterium tuberculosis. Once the global emergency was declared in 1993, seeking out
new drugs became urgent. In this book, diverse authors focus on the development and the activity of the new
drug families.
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